RICE UNIVERSITY

Using Multiple Imputation, Survival Analysis, And Propensity Score Analysis In Cancer Data With Missingness

by

Nathan Karmazin Berliner

A THESIS SUBMITTED IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE

Master of Arts
Statistics

APPROVED, THESIS COMMITTEE:

Rudy Guerra, Committee Chair
Professor of Statistics

Kenneth Hess, Thesis Director
Professor, MD Anderson Cancer Center

Yu Shen
Professor, MD Anderson Cancer Center

Marina Vannucci
Professor of Statistics

David Scott
Professor of Statistics

Houston, Texas
December, 2015
ABSTRACT

Using Multiple Imputation, Survival Analysis, And Propensity Score Analysis In Cancer Data With Missingness

by

Nathan Karmazin Berliner

In this thesis multiple imputation, survival analysis, and propensity score analysis are combined in order to answer questions about treatment efficacy in cancer data with missingness. While each of these fields have been studied individually, there has been little work and analysis on using all three together. Starting with an incomplete dataset, the goal is to impute the missing data, and then run survival and propensity score analysis on each of the imputed datasets to answer clinically relevant questions. Along the way, many theoretical and analytical decisions are made and justified. The methodology is then applied to an observational cancer survival dataset of patients who have brain metastases from breast cancer to determine the effectiveness of chemotherapeutic and HER2-directed therapies.
Contents

Abstract i
List of Illustrations iv
List of Tables v

1 Introduction and Background Information 1
  1.1 Motivation ......................................................... 1
  1.2 Missing Data ..................................................... 2
  1.3 Survival Analysis ............................................... 5
  1.4 Causal Analysis .................................................. 9

2 Methods 15
  2.1 Multiple Imputation .............................................. 15
    2.1.1 Selecting the MI Scheme ................................... 16
    2.1.2 Setting and Checking the Imputation Model ............... 21
    2.1.3 Combining the MI Estimates ................................. 23
  2.2 Survival Analysis ............................................... 26
    2.2.1 Kaplan-Meier Survival Curve ............................... 26
    2.2.2 Median Survival Time ....................................... 27
    2.2.3 Log Rank Test ............................................... 28
    2.2.4 Cox Proportional Hazards Model ............................ 29
  2.3 Causal Analysis .................................................. 31
    2.3.1 Selecting the Method ....................................... 32
    2.3.2 Obtaining the Propensity Score ............................. 33
    2.3.3 Verifying Balance ............................................ 35
3 Application 37
  3.1 Data Explanation ........................................ 37
  3.2 Imputation ............................................... 40
  3.3 Survival Analysis ........................................ 48
  3.4 Causal Analysis .......................................... 58

4 Discussion 65

5 Conclusion 70

A Appendix 71
  A.1 Missing Data Mechanisms ................................. 71
  A.2 Cancer and Treatment Overview ....................... 75

Bibliography 77
Illustrations

1.1 Example of the MI process ........................................... 5

2.1 Normal JM imputation pseudocode ................................. 17
2.2 MICE FCS imputation pseudocode ................................. 20

3.1 Visualization of missingness in the cancer dataset ............. 39
3.2 Selected convergence plots of continuous variables .......... 45
3.3 Selected convergence plots of binary variables ................. 45
3.4 Selected density plots of continuous imputed variables ...... 46
3.5 Selected box and whisker plots of continuous imputed variables ...... 47
3.6 Selected histograms of the ratio of imputed variables ....... 47
3.7 Landmarked Kaplan-Meier curves for chemotherapeutic drugs, AC
and MI data .......................................................... 50
3.8 Landmarked Kaplan-Meier curves for HER2-directed drugs, AC and
MI data ............................................................ 51
3.9 AC Schoenfeld residuals over time ................................. 53
3.10 MI Schoenfeld residuals over time ................................. 54
3.11 Selected propensity score distribution checks ................ 61
3.12 Selected propensity score balance checks ...................... 62

A.1 Visualization of Missing Data Mechanisms ..................... 74
Tables

3.1 Data categories and examples ........................................ 38
3.2 Table of important covariates to be used in the analysis ............. 38
3.3 Characteristics of AC data versus MI data ............................ 48
3.4 Chemotherapeutic drugs log rank tests .............................. 52
3.5 HER2-directed drugs log rank tests ................................... 52
3.6 AC and MI baseline Cox model ...................................... 55
3.7 AC and MI Cox model with chemotherapeutic treatments ........... 56
3.8 AC and MI Cox model with HER2-directed treatment, on HER2+ subjects ................................................................. 57
3.9 Unadjusted Chemotherapeutic ATE with IPTW, AC and MI .......... 63
3.10 Chemotherapeutic ATE, doubly robust adjusted IPTW estimate, AC and MI ............................................................. 63
3.11 Unadjusted HER2-directed ATE with IPTW, AC and MI ............. 64
3.12 HER2-directed ATE, doubly robust adjusted IPTW estimate, AC and MI ................................................................. 64
Chapter 1

Introduction and Background Information

1.1 Motivation

The motivation of this thesis is to show the methodology that can be used by both applied researchers and clinicians to draw meaningful survival and causal inference from observational data with missingness. While all three fields (missing data, survival analysis, and causal analysis) are well studied, their interaction is not. I want the methods to be easy enough to describe to someone with a limited statistical background, but meaningful and valid so that the results obtained can be used in publication. The desire to have it this way stems from working on a related project with both statisticians and clinicians. While this thesis is motivated by cancer data, I believe that the methods used in this thesis are general enough to be applied to other types of data and situations.

Missing data is a major problem in both statistics and medicine; however, it has not received attention proportional to its need. Survival analysis is well studied, but is relatively complete, so new research is seldom produced. Propensity score analysis will help us determine causal relationships when we don’t have a randomized controlled experiment. As one could imagine, all three of these fields are important to the applied statistician, as they will come across issues in each discipline at least one at some point in their career. The goal of this thesis is to demonstrate how to use all three in trio, a topic that has only received little interest in the literature.
In Chapter 1 of this thesis, each of these three disciplines will be described in
detail separately. In Chapter 2, the methodology for using all three of them together
will be discussed. In Chapter 3, the methods will be applied to a cancer dataset.
Finally, in chapters 4 and 5 the implications and conclusions will be discussed.

1.2 Missing Data

In an ideal world, we would have complete data with no missingness; however this
is rarely ever the case. To be specific about the definition of the word, missing
data/missingness is when a subject’s data for a collected covariate was not obtained.
Missing data is not when a covariate is never collected, and then suddenly the re-
searcher wishes he had collected it. Imputation (specifically multiple imputation) is
a way to “fill in missing data” with plausible values, and it forms the base of this
thesis. Imputation itself has been around since the 1930’s [1], but multiple imputation
is a recent development, proposed in the 1970’s and formalized in 1987 by Donald
Rubin [2]. To understand the use and importance of multiple imputation, we need to
understand the problem of missing data, and the previous attempts to deal with it.

At first, statisticians paid no attention to missing data, and happily discarded
records from their data that were incomplete. This procedure is known as Complete
Case (CC) analysis. There are many problems with this paradigm. To begin with,
you will lose a lot of statistical power under CC analysis, because you are throwing
away records and thus decreasing your sample size. In addition, this can be costly (in
terms of time or money) to the researcher, because they had to actually obtain these
records that are not used. Lastly, and most importantly, any estimate obtained from
a CC analysis is likely to be biased. For example, suppose we have a random sample
of people and are testing a drug’s efficacy, and want to run a regression on some
collected covariates. If men are known to not want to give all of their information, in the analysis, we will need to discard the male samples because they are incomplete, leaving us only with women. Thus, we no longer have a random sample, and will get biased results because we have knowingly thrown away half of our data which we know to be different [1].

A slight improvement on this is called Available Case (AC) analysis. In this setting, a record is used in the analysis if it has all of the needed information for that analysis at hand. So, a record could have missingness, but if the covariate with missingness is never used in the analysis, the record will not be discarded. This paradigm is the standard analysis type for most statistical packages. It is better than CC analysis, but is still flawed. We are still throwing away valuable data as we were with complete case analysis, although likely not as much. AC analysis will still lead to bias in the same way that complete case did too. As well, new complications arise in AC analysis, namely that nonsensical situations like correlations outside of ±1, and inconsistent sample sizes between different analyses.

The next wave of statisticians in the early 20th century wanted to improve upon available case analysis, so they developed what we now call today (single) imputation. Their goal was to fill in missing values with a single plausible replacement value. A single method (such as regression, taking the mean, resampling, etc.) is used one time to impute or fill in the missing value, and to account for the uncertainty, degrees of freedom are deducted in the following analysis. While this is a little better than complete case analysis, it still has many drawbacks. Asserting that a single value is the true value is unjustified. There is always some amount of error and uncertainty involved, and we can in no way be 100% confident that our imputed value is correct. Furthermore, if I impute one value and you impute another, we may get completely
different results from analysis on the data. This is obviously not a desirable trait. In addition, one single imputed dataset will artificially increase your sample size. You are in effect treating the imputed values as if they were real, inflating your sample size with data that was not actually observed. This will give you unjustified statistical power and accuracy. While single imputation certainly has its drawbacks, the idea of actually trying to fill in the data (rather than throwing it away) is an important one, and multiple imputation fills in the gaps that single imputation is not able to cover.

Multiple imputation (MI) began in the 1970’s, but it wasn’t until 1987 when Donald Rubin formalized multiple imputation methodology in his seminal book *Multiple Imputation for Nonresponse in Surveys* did it start to gain acceptance [2]. The central idea is to frame the problem in a Bayesian framework, and produce \( m \geq 2 \) values to substitute in for each missing value, drawing these values from the missing covariates posterior distribution. Using these \( m \) substitute values, we can think of the data now as being \( m \) datasets, each dataset containing the observed data, and one value for each piece of missing data.

An example will make the MI process clear. Suppose that we had a dataset of age, weight, and height. We want to do a linear regression of weight on age but we have missingness in weight and height. First, we will impute our data (figure 1.1, the first two columns). Once we have a sufficient number of datasets (we will talk about how to pick the number later), we can run the regression analysis on each of the MI datasets, treating the dataset as if it was complete (horizontal lines and third column). After running the model on the \( m \) datasets, we can pool the results to get one single estimate with its associated variance (last column). We will speak of the exact details of the MI process in detail in the second chapter.

The MI method is obviously much better than the previous attempts to correct
Figure 1.1: Example of the MI process

In the original data, missingness is displayed by ‘?’s and the imputed data is shown in the multiply imputed data as ‘#’s. We then regress weight on age in each MI dataset, get the results from each, and then pool them together.

for missing data because it permits us to keep the data we already have, as well as to quantify our uncertainty about imputing the missing values.

The use of MI has been steadily increasing over the past 30 years, and it is now the standard for missing data. It has seen a great increase in use in the medical field, but has yet to see mainstream success in the statistical community.

1.3 Survival Analysis

Survival analysis is a large and important field in statistics, and there have been many textbooks written about it. I only plan to introduce the topics that are relevant to my case study; for a much more detailed account of survival analysis, please see reference
Survival analysis on the whole can generally be described as the analysis of time to event data, often in the presence of censoring (when we don’t have complete information about the time of event). There are many techniques used in this field, but the main tools that we will be using are Kaplan-Meier estimates, log rank tests, and Cox regression.

Before we go on, it should be noted that often in the literature and software (and in this paper) we see terms like “death/failure” and “survivors”. This is due to survival analysis being heavily influenced and intertwined with medical studies. A more general term for these would be “event” and “those who have not had an event yet”. These terms are used because they are clear and concise, although it might not accurately describe the event at hand. For example, if we were tracking the time until a child loses all of their baby teeth, the term death would obviously not portray the event of interest, but may be used in the context to denote losing all of the teeth.

The Kaplan-Meier (KM) estimator is a nonparametric estimate of the true survival function (the probability of survival after time $t$, $S(t) = P(T > t) = \int_t^\infty f(u)du$, where $f(u)$ is the unknown probability density function). It is defined as

$$\hat{S}(t) = \prod_{t_i < t} \frac{n_i - d_i}{n_i}$$

where $n_i$ is the risk set, defined as the number of people who have not had the event or been censored right before time $t_i$, and $d_i$ is the number of deaths observed at time $t_i$ [4]. The Kaplan-Meier estimator is very commonly used as a measure to see how different treatments affect the survival of the population in question, and is helpful in seeing at what time points survival changes the most (i.e. early or late).

Knowing the shape of the Kaplan-Meier curve is interesting and gives a good graphical representation of survival over time, but it would be wise to have a statistical
test to compare survival two curves. The log rank test is a popular nonparametric test that researchers often use to see if two or more survival curves come from the same distribution [5]. This is a useful tool to have, because visualizing curves alone does not give us this information. We could have two curves that look radically different due to sampling error, yet still come from the same distribution.

The general log rank test is defined as:

$$\frac{\sum_{j=1}^{J} w_j(O_{1j} - E_{1j})}{\sqrt{\sum_{j=1}^{J} w_j^2 V_j}} \sim N(0, 1)$$

Where $w_j$ is the weight of each individual (must be $\geq 0$, we will set all to be 1), and $N_j = N_{1j} + N_{2j}$ is the number of subjects in the risk set at time $j$, composed from the sum of the number of deaths at time $j$ in each group, $O_j = O_{1j} + O_{2j}$ is the observed number of deaths at time $j$, composed of the sum of deaths from either group at time $j$, which leads to the desired quantities $E_{1j} = \frac{O_j N_{1j}}{N_j}$, and $V_j = \frac{O_j (N_{1j}/N_j)(1-N_{1j}/N_j)(N_j)/N_j}{N_j - 1}$.

Typically, all of the weights are set to one, as this test places equal weight to all of the deaths we observe. We could change these weights though to give more emphasis to certain death times. This is useful for example if we have a drug that takes a long time to start working. We wouldn’t care about early deaths, only about later times when we are comparing the survival. Putting more weight on the later deaths would help to answer this question better. It can be proven that the log rank test is equivalent to the score test on a Cox model (which will be discussed next) fit the same data with no tied event times, and very similar when there are ties [3].

Proportional hazards regression, often called Cox regression or Cox model is a modelling tool that allows us to analyze the hazard ratio of a covariate, assuming that each covariate acts to multiply the hazard ratio.

In order to understand Cox regression, we first need to learn about the hazard
function. The hazard function is a survival tool that tells us the rate of events at time $t$, conditional on survivorship until time $t$. Mathematically, it is given by:

$$\lambda(t) = \lim_{\Delta t \to 0^+} \frac{P[t \leq T < t + \Delta t | t \leq T]}{\Delta t}.$$ 

Cox regression is a maximum (partial) likelihood method estimator, given by:

$$h(t|Z) = h_0(t) \exp(\sum_{k=1}^{p} \beta_k Z_k).$$

where $h_0(t)$ is what’s known as the baseline hazard, and can be any positive function. Note how it only depends on time and not any covariates. $Z$ is a vector of observed covariates, and does not depend on time. The $\beta$’s are found by maximizing the partial likelihood function

$$L(\beta) = \prod_{i=1}^{D} \frac{\exp(\sum_{k=1}^{p} \beta_k Z_{(i)k})}{\sum_{j \in R(t_i)} \exp(\sum_{k=1}^{p} \beta_k Z_{jk})}.$$ 

Where $Z_{(i)k}$ is subject $i$’s $k$th covariate, $R(t_j)$ is the risk set (set of those who have not died yet at the time just prior to $t_j$), $D$ is the number of distinct death times and $p$ is the total number of covariates in the model [6].

Our inference of interest is on the hazard ratio, given by $\frac{h(t|Z)}{h(t|Z^*)} = \exp(\sum_{k=1}^{p} \beta_k (Z_k - Z^*_k))$, where $Z^*$ is another set of covariates. The hazard ratio describes how the hazard changes between individuals with different covariates. Often times, the interest lies in what happens when all covariates are held constant, and the covariate of interest is increased one unit (or if a categorical variable, changing groups). This ratio will be a constant, and should not vary over time; hence the name proportional hazards. This is so because the ratio does not depend on the baseline hazard (which cancels out when taking the ratio). Using Cox regression, statements such as “Increasing the drug by one mg will decrease the rate of death (compared to non-users) by 30%”. Cox modelling is one of the most used models in the survival and medical literature,
because it is flexible, powerful, easy to use, and incorporates other covariates into the survival model.

1.4 Causal Analysis

In an ideal world we would like to be able to do research and say that A causes B, rather than “our study says that A is associated with B”. However, the only way to get this interpretation is if we conduct a Randomized Controlled Trial (RCT). Although we can analyze any observational data using survival analysis, unless an RCT is conducted, we can only make claims about association, not causation. In order to prove causality, we need experimental data in a randomized and controlled setting, not observational data. The reason for this is because in an RCT, we expect the groups to be similar at baseline (due to randomization), and thus any differences between the groups after treatment should only be related to the treatment. However, in an observational study (where treatment assignment is not random, and may even by chosen by the participant), we have no reason to believe the groups are similar at baseline (in fact, they might be systematically different), and the difference after treatment could be due to the treatment or something else.

Randomized controlled trial is a term that is often thrown around, but I want to be precise with its definition. An RCT is a study design that “randomly assigns participants into an experimental group or a control group. As the study is conducted, the only expected difference between the control and experimental groups in an RCT is the outcome variable being studied” [7]. This is in stark contrast to a retrospective study of observational data, where historic data of people who chose what group/treatment they wanted to be in are studied. When making judgment on a retrospective study, we cannot be sure if the differences between the groups are
due to their treatment choice, or some other factor. RCT’s are the gold standard for experiments, and should be used if possible when trying to study causality. But often times monetary, ethical, and other factors prevent us from doing so. In this case, the best data we may be able to get is retrospective observational study.

Luckily, we can still analyze observational data for causality. We can frame our problem in a framework known as the Rubin Causal Model, which helps get causal understanding from non-experimental settings [8]. Rubin’s causal model is built upon the idea of a counterfactual, also known as a potential outcome. Put simply, the counterfactual is the result that we would have observed had the subject been in the other group. For example, if we were testing a weight loss drug versus a diet in a study to see which lead to more weight loss, if subject 1 took the drug, then his observed value would be the weight lost on the drug, whereas his counterfactual would be the weight lost had he dieted. Together, the observed value and the counterfactual form what is known as the potential outcomes. For the $i^{th}$ subject, the potential outcomes are denoted as $Y_i(0), Y_i(1)$, where the 0 means treatment and 1 means control. Often times, authors give the observed value concisely as $Y_i = Y_i(1)T_i + Y_i(1-T_i)$, where $T_i$ is the treatment indicator (1 means treatment, 0 means control). In an ideal world, we would observe both potential outcomes, however, this is obviously not possible, since we can only observe one outcome. This issue is what is known as the fundamental problem of causal inference.

Rubin’s Causal Model framework relies on two assumptions. The first is called the stable unit treatment value assumption (SUTVA), which states that the potential outcome for the $i^{th}$ subject will be the same no matter what treatment the other subjects receive. The second is called ignorable treatment assignment (sometimes called no unmeasured confounders), which states that the potential outcome should be in-
dependent of the treatment assignment given the confounding factors. Put formally, this condition is \((Y_0, Y_1) \perp T \mid X\), where \(X\) are the pretreatment covariates confounding the potential outcomes and the treatment assignment [8]. This assumption is untestable, but can be reasonably assumed in most cases if we do the propensity score analysis correctly (which we will talk about soon). This assumption is satisfied automatically in an RCT, because knowing treatment assignment doesn’t give any information about the potential outcomes. If we are able to meet these assumptions, then using Rubin’s causal model will help us make causal inference from non-RCT data, as we will discuss.

If we are able to get the counterfactual, we could compute the treatment effect of the treatment for each individual. However, this is not of much interest to us. Rather, we are interested in the treatment effect on the entire population, not the individual. There are two common estimands used to measure the causal effect in the population. The first is the Average Treatment Effect (ATE), and it is defined as how the treatment effect changes when the population moves between treatment groups. It is given mathematically by \(E[Y(1) - Y(0)]\). The other measure is called the Average Treatment Effect on the Treated (ATT), which is the treatment effect of one group moving to another treatment is given by \(E[Y(1|T = 1) - Y(0|T = 1)]\).

It should be noted that unless we have the no unmeasured confounders assumption \(E[Y(1)|T = 1] \neq E[Y(1)]\), because \(E[Y|T = 1] = E[Y_1 T + Y_0 (1 - T)|T = 1] = E[Y_1 |T = 1] \neq E[Y(1)]\). And the same holds for \(Y(0)\), such that \(E[Y(0)|T = 0] \neq E[Y(0)]\). If we were to use \(E[Y(1)|T = 1], E[Y(0)|T = 0]\) as substitutes for \(E[Y(1)], E[Y(0)]\) in our calculations, we would get biased estimation of the treatment effect. What this means is that if we are not in the causal framework or in an RCT, then we cannot split the expectation up and just take the mean from each
group to get the causal effect. However, if we are in the causal framework, and we assume no unmeasured confounders, then $E[Y(1)|T = 1, X] = E[Y(1)]$ because the potential outcome is independent of the treatment assignment, and the same holds for the control group. If the potential outcomes were independent of the treatment assignment (like in an RCT), then we could break apart the expectations and calculate the estimands as the difference in the expected values between the treated and control group. But since we don’t get this automatically satisfied in an observational study, we need to develop methods to help us get this interpretation.

The goal of randomization in RCT’s is to make the groups be as similar as possible at baseline, that is, the distribution of the pretreatment covariates should not be too different. However, in an observational study, the groups may be very different. It is quite likely that some baseline factor might influence how somebody picked their treatment. In the weight loss pill example, healthier people may choose the diet over the pill, whereas people motivated to lose weight might be inclined to take the pill, so the participants in the two groups will not be similar to start with. We should try to make them more similar (i.e. balanced) if we wish to emulate an RCT.

In order to implement balancing in Rubin’s causal model, *propensity score analysis* is used. The propensity score is the probability that the subject received the treatment given the pretreatment covariates that are believed to be confounded with treatment choice. The propensity score for the $i^{th}$ subject is given by $\hat{e}_i(X) = P(T_i = 1|X_i = x)$ and can be found by any method that gives group membership probabilities [9]. We assume that some of the pretreatment covariates confound treatment status and outcome, so controlling for this makes all of the patients seem similar at baseline. Because of the propensity score theorem, if we have ignorability, then we say that $(Y_0, Y_1) \perp Z|\hat{e}(X)$, [10]. With the no unmeasured confounders assumption, we must
condition on a vector to get independence, however, the appeal of the propensity score is that we can get the same assumption by only conditioning on a scalar quantity (the propensity score).

Propensity scores lead to group balancing, that is, if propensity scores are controlled, then our groups will have a similar distribution for each baseline covariate at the start of the study. Put formally, propensity scores aim to remove the confounding between pretreatment characteristics and treatment. And thus, by controlling for propensity score and using Rubin's causal framework, we can treat the data like it was an RCT. The most popular propensity score methods are propensity score matching (where we match those who picked the treatment to those who did not based on propensity score similarity) and propensity score weighting (where each individual's contribution to the average treatment effect is dependent on the inverse of their propensity score). Propensity score matching has fallen out of favor recently because there will be some data thrown away, and the balancing that follows might not be that accurate [11]. However, propensity score weighting is still a popular method today [12].

Getting the propensity score was historically done by logistic regression, although recently newer machine learning methods have been employed. Any method that will lead to probability of treatment or control membership will suffice. There has been a lot of debate as to which covariates to include in the propensity score; either all variables, or only relevant variables, but I don’t aim to settle this debate in this paper.

This paper is interested in weighting, specifically, inverse probability of treatment weight (IPTW). With IPTW, the sample is reweighted so that at baseline, the groups
appear similar. These weights are given by

$$w_i = \frac{T_i}{\hat{e}_i(X)} + \frac{1 - T_i}{1 - \hat{e}_i(X)}$$

and thus the weighted response will be \(\frac{TY}{\hat{e}(X)}\) for the treated and \(\frac{(1-T)Y}{(1-\hat{e}(X))}\) for the untreated.

The idea of IPTW weighting is to reweight the sample so that we get a population where there is no confounding, and the weighted averages reflect the true population averages. Its justification is due to the fact that it can be proven that \(E[\frac{TY}{\hat{e}(X)}] = E[Y(1)]\) and \(E[\frac{(1-T)Y}{(1-\hat{e}(X))}] = E[Y(0)]\) [12]. Because of this, the IPTW outcome from each of the groups can be treated as if it has been obtained from randomization, and we may treat it as such.
Chapter 2

Methods

In this section, the ideas presented in the previous section will be brought together. I want the framework and methods used to be easy to use and understand, so that it can be discussed among clinicians and other people who don’t have a statistics or mathematics background. On the same token, I want the methods and theory to be sound from a statistical point of view. There are many different theories and implementations to choose from for the three topics covered in this thesis. I aim to pick the ones that optimize ease of understanding and power of results, with the motivating example being cancer survival data. Throughout this section, decisions must be made as to what methods and analyses to use. Whenever a decision is made, I explain why it was chosen as well as alternative methods that could also be used. It is my hope that I will provide enough clarity and detail so that the interested reader can intelligently apply these methods to their own data, even if the choice of methods is different than this thesis.

2.1 Multiple Imputation

It should be clear that multiple imputation is the preferred method to deal with missing data, so our first decision comes as to what paradigm to impute under. As long as valid imputations are produced, the choice of method to generate the imputations does not matter. However, since the base of our analysis starts with
imputation, we need to make sure that we pick a good method. Everything that follows in the analysis is dependent on our imputed data, so it is necessarily the case that poor imputations will lead to poor results be it bias, high variability, or loss in statistical power.

2.1.1 Selecting the MI Scheme

Before we get in to the imputation models, we need to have a firm understanding of missing data concepts. They take up quite a bit of space to explain, but they are fundamental concepts. Please read appendix A.1 (even if you are familiar with MI), so that the concepts and symbols that will be used in this paper are understood and standardized.

There are two main divisions in modern multiple imputation: joint modelling and full conditional specification. Both have their own advantages and flaws. I will describe both, and then explain why full conditional specification is better suited for cancer research.

The first main imputation strategy is called Joint Modelling (JM). In JM, we assume that the missing data mechanism is ignorable and that the data can be described by a multivariate distribution specified by the user on the rows (missing data pattern) of the data. Then, we run a sampler that draws imputations from the specified model, and updates model parameters. Since the true model parameters are unknown, they need to be estimated. This is often done by a data augmentation algorithm [1]. A pseudocode example will help better clarify the steps, as can be seen in figure 2.1, where the assumed model is a multivariate normal.

There has been extensive programming and research on using the normal model for JM, and research shows that it even performs well under situations where the data
1. Sort the rows of $Y$ into $S$ missing data patterns $Y_{[s]}$, $s = 1, \ldots, S$.
2. Initialize $\theta^0 = (\mu^0, \Sigma^0)$ by a reasonable starting value.
3. Repeat for $t = 1, \ldots, T$:
4. Repeat for $s = 1, \ldots, S$:
5. Calculate parameters $\hat{\phi}_s = \text{SWP}(\hat{\theta}^{t-1}, s)$ by sweeping the predictors of pattern $s$ out of $\hat{\theta}^{t-1}$.
6. Calculate $p_s$ as the number missing data in pattern $s$. Calculate $a_s = p - p_s$.
7. Calculate the Choleski decomposition $C_{s}$ of the $p_s \times p_s$ submatrix of $\hat{\phi}_s$ corresponding to the missing data in pattern $s$.
8. Draw a random vector $z \sim N(0,1)$ of length $p_s$.
9. Take $\hat{\beta}_s$ as the $a_s \times p_s$ submatrix of $\hat{\phi}_s$ of regression weights.
10. Calculate imputations $Y_{[s]}^{*t} = Y_{[s]}^{\text{obs}} \hat{\beta}_s + C^t_s z$, where $Y_{[s]}^{\text{obs}}$ is the observed data in pattern $s$.
11. End repeat $s$.
12. Draw $\hat{\theta} = (\hat{\mu}, \hat{\Sigma})$ from the normal inverted-Wishart distribution according to Schafer (1997, p. 184).
13. End repeat $t$.

Figure 2.1: Normal JM imputation pseudocode

Taken from van Buuren’s book Flexible imputation of missing data [1]

has strong non-normality [13]. Not much research has been done on models outside of the normal.

This is just one implementation of a JM approach. Another, like that used in the Amelia package, uses an EM algorithm to draw from the missing data’s posterior assuming a normal likelihood and user specified priors [14]. Other distributions can be used, but the user will have to specify it, derive any relevant distributions, program it, and research to see if the method provides optimal properties, such as proper
coverage and correct estimation of the parameters of interest.

An obvious issue with JM arises when the data is categorical (either alone or mixed in with continuous). There has been much debate in the literature about how to handle this situation. Some authors argue that you should just impute under a continuous distribution and round imputations to the nearest category number, and others suggest using distributions that are more suited for categorical data [1]. However, no consensus has been reached on the best method. The issue still remains that JM handles mixed data very poorly.

It is my opinion that unless the user is very confident in the multivariate joint distribution of where the data comes from, that JM should not be used. While JM is theoretically sound, its assumptions are so strict that it is nearly unusable in practice. In the cancer example, there are many categorical variables and strictly non-negative variables to impute, so JM seems inappropriate.

The other MI strategy is called fully conditional specification (FCS). In this paradigm, missing data is assumed to be MAR (although it can work on MNAR with more assumptions), and is imputed on a variable by variable case on the columns/covariates based off of user specified imputation models. Whereas JM imputes on the rows, FCS imputes on the columns. Imputations are drawn from the missing data’s posterior predictive distribution. This theory goes by many names, including partially compatible MCMC, iterated univariate imputation, and chained equations [1]. In the JM setting, the user must give one $p$-dimensional model, however in the FCS setting, the user must give $p$ one-dimensional models. The goal of FCS methods are to sample from

$$P(Y, R|\theta)$$
By sampling from the full conditionals

\[ P(Y_j | Y_{-j}, R, \theta_j) \]

In this notation for the previous two equations, \( Y \) is the fully observed data, \( Y_{-j} \) means all of the columns of the data except for \( j \), \( R \) is the missing data indicator, \( \theta \) is the vector that parameterizes the full data model, and \( \theta_j \) parameterizes the imputation model. A pseudocode example can be seen in figure 2.2. This method is called Multiple Imputation by Chained Equations (MICE), and draws the imputations from the posterior predictive density of each missing covariate in an iterative fashion. The imputation models in step 1 can either be parametric distributions, or models (such as regression, predictive mean matching, etc.), that are specified by the user. Note that the previous imputations enter the current imputation only through the relation with the other variables (step 5), and not directly. Because of this, convergence is often seen within 5 iterations [15]. The values at the last iteration are taken as the draws from the missing data’s posterior, and these are the values used to fill in the missing data.

One of the major criticisms of this method is that in order for there to be a guarantee that we are sampling from the correct distribution, we need to ensure that our full conditionals are compatible, i.e. that they factor into the proper, explicit joint. This is very hard to check in practice, but multiple studies have shown that even when the models are highly incompatible, FCS methods are very robust and produce proper imputations [16]. FCS allows us much more flexibility than JM does since each model is under the user’s control, and it handles mixed categorical and continuous data much better than JM does [17]. In addition, specifying the individual model for each covariate allows the user to handle the intricacies of each covariate.

The user is going to have to specify something, there is no escaping that, but it is
1. Specify an imputation model $P(Y_j^{\text{miss}}|Y_j^{\text{obs}}, Y_{-j}, R)$ for variable $Y_j$ with $j = 1, \ldots, p$.

2. For each $j$, fill in starting imputations $\hat{Y}_j^0$ by random draws from $Y_j^{\text{obs}}$.

3. Repeat for $t = 1, \ldots, T$.

4. Repeat for $j = 1, \ldots, p$.

5. Define $\hat{Y}_{-j}^t = (\hat{Y}_1^t, \ldots, \hat{Y}_{j-1}^t, \hat{Y}_{j+1}^t, \ldots, \hat{Y}_p^t)$ as the currently complete data except $Y_j$.

6. Draw $\hat{\phi}_j^t \sim P(\phi_j^t|Y_j^{\text{obs}}, \hat{Y}_{-j}^t, R)$.

7. Draw imputations $\hat{Y}_j^t \sim P(Y_j^{\text{miss}}|Y_j^{\text{obs}}, \hat{Y}_{-j}^t, R, \hat{\phi}_j^t)$.

8. End repeat $j$.

9. End repeat $t$.

Figure 2.2: MICE FCS imputation pseudocode

Taken from van Buuren’s book Flexible imputation of missing data [1]

easier for the average person to be able to define a single distribution and model rather than to guess at a multivariate distribution, particularly if it is high dimensional. In addition, in the survival analysis setting, there will naturally be strictly non-negative and categorical variables. Trying to fit a parametric distribution with these stipulations will be very hard if not impossible, so we will be relegated to using a general distribution (like the normal), which will certainly elicit a poor fit. So, JM approaches certainly seem ill-fitting, however FCS approaches are very appealing.

In order to use FCS methods properly, the missingness in our data must be MCAR or MAR. It can work with MNAR missingness, but it requires some extra modelling assumptions that are beyond the scope of this thesis. T tests have been proposed to test if the data is MAR or MCAR, but this is of little use for us, because we only want
to know if the data is MNAR, which is impossible to test since testing for MNAR would entail us using information that is impossible to get [18]. Luckily, we can safely assume MAR if there is reason to believe that some of the covariates collected account for the missingness [1].

It should be noted that in the real data we will use, the response variable (survival time) is fully observed, but the covariates have a lot of missingness. If it were the case that we had missingness in the survival time, then the methods described above might not work. They might fail because the unobserved times or outcomes may follow a different distribution than the observed times. This is cleared up by Zhao et. al in 2014 through Kaplan-Meier MI [19]. This is beyond the scope of this report though so I omit its details.

2.1.2 Setting and Checking the Imputation Model

Once we have checked that the MAR assumption is true, we need to set up our full conditional imputation models. This may take a while for large datasets, but the extra time spent will ensure a better and move valid imputations. We choose what method to use (regression, predictive mean matching, logistic regression, trees, parametric distribution, etc.), and then what predictors will go into those models. We should choose predictor variables that help explain missingness, as well as those we are doing inference on, as to avoid bias [1]. For variables that are derived from others, we impute its components and then compute that variable, in a process known as passive imputation. With large datasets, we may need to perform variable selection before specifying the models, so that setting up the models doesn’t become unmanageable.

Since FCS is an iterative process, we must choose how many iterations to do until convergence. The older literature suggests 5 iterations are enough, but with
modern computation, we can easily exceed this, even with large data [1]. A good way to assess how many iterations to run is to look at the trace plots of the imputed values and then add 5 iterations to the number at which we assume convergence is achieved. Due to the nature of FCS methods, convergence is often very quick, often as soon as 5 iterations. As well, we need to decide how many datasets to impute. The early literature argued that 5 datasets would suffice, but modern literature argues for more, since it will cut down on simulation error. With the speed of computers and availability of storage, many authors now suggest using more than 5 imputations [1]. Many different authors have different criteria, but a popular criterion is to impute as many datasets as the 100 times the percentage of cases in the analysis with missingness [20].

Once we have determined how many iterations and imputations to use, the FCS algorithm is run. Depending on the model specifications, it should not take too long for small datasets (seconds or minutes), but may take hours for larger ones. FCS models often converge quickly, so after convergence, we are just taking draws from the missing covariates posterior. The first few iterations may be considered as burn in, and the rest as samples. The value at the last iteration of each chain is taken as the sample from the posterior that will be used as the value for the missing data.

We need to verify that our imputations are valid once we complete them. First, we need to see if our chains have converged. Since FCS methods are essentially Markov Chain Monte Carlo MCMC methods (under compatibility, they are a Gibbs sampler), we should check the chains for irreducibility, aperiodicity, and recurrence. To determine when the chains have converged, van Buuren suggests that “Convergence is diagnosed when the variance between different sequences is no larger than the variance within each individual sequence” [1]. There is some research (but not from the
MI perspective) about tests to check for convergence, and a popular test is Gelman and Rubin’s $\hat{R}$ scale reduction factor test [21]. This test is often used in conjunction with visual tests. Assessing convergence by looking at of all of the values over $m$ imputations and $k$ iterations would be very hard to visualize because there would be so many chains, so often times, we will choose to observe a statistic (like the mean) of the chain and assess on that.

Once convergence is assessed, we need to check that the values imputed are valid and come from the correct posterior. This will serve as our model checking and validation. The overarching idea that we need to pay attention to is does the data look like it could have been real data. We can assess this in many ways, including density plots, box and whisker plots, scatterplots, histograms, etc. This is a visual task and there is no statistical method to validate this.

This whole process can be very time consuming because every time we want to make a change in the methods used, we have to rerun the algorithm and reassess our results. But once we find the setup that works for us, we don’t need to repeat it again. So, while it may take a lot of time now, setting up a proper model will save us even more time in the future and ensure that our imputations are valid.

2.1.3 Combining the MI Estimates

Once the $m$ datasets are imputed, we may run any valid analysis on each imputed dataset individually, treating each of the $m$ datasets as if it was complete. Of course, the analysis in question should be run on the available cases, to ensure that the model assumptions are reasonable. We will speak about what exact analyses will be run in the next sections, but for this section, we focus on how to combine any analysis.

The idea of what we would like to do is to take the $m$ estimates of the scientific
estimand in question, and pool them down into one single estimate. Rubin’s rules are a set of rules that guide us in making inference from multiply imputed data. They will give us a single point estimate for the scientific estimand in mind, as well as the proper variance for it from the \( m \) imputed datasets [2].

Rubin’s rules involve three parts. The first is getting an estimate of the population estimand \( Q \), estimated with the MI datasets by \( \hat{Q} \). To get \( Q \), define \( \hat{Q}_i \) as the estimand evaluated from the data in the \( i^{th} \) dataset. Then, take the average over all \( m \) datasets to get a single estimate \( \bar{Q} \).

\[
\bar{Q} = \frac{1}{m} \sum_{i=1}^{m} \hat{Q}_i
\]

The estimates are not set, and there is variance associated with them. The first form of variance is the “within” variance, or the variance of each estimate \( \hat{Q}_i \). This is the typical variance observed from having a sample. Define the variance covariance matrix of the \( i^{th} \) imputed estimand as \( \bar{U}_i \), then the estimate of the within variance is computed as

\[
\bar{U} = \frac{1}{m} \sum_{i=1}^{m} \bar{U}_i
\]

The last form of the variance is the “between datasets” variance. This is the variance associated with the fact that we have missing data. It is given by

\[
B = \frac{1}{m-1} \sum_{i=1}^{m} (\hat{Q}_i - \bar{Q})(\hat{Q}_i - \bar{Q})'
\]

The total variance for \( \bar{Q} \) is given by

\[
T = \bar{U} + B + \frac{B}{m}
\]

The last term is our simulation variance, and its existence is proven by Rubin in [2]. The theory of inference with Rubin’s rules is rooted in the assumption that under repeated sampling, the complete data quantity of interest is \( Q - \hat{Q} \) asymptotically
normally distributed with mean 0 and variance $U$, where $U$ is the variance of $(Q - \hat{Q})$ [1]. We don’t have the true population variance, so we must use what we have from the sample, namely $T$, the MI total variance. With this assumption, we know that

$$\frac{Q - \hat{Q}}{\sqrt{T}} \sim t_\nu$$

And the degrees of freedom is proven to be

$$\nu = \frac{\nu_{old}\nu_{obs}}{\nu_{old} + \nu_{obs}}$$

Where $\nu_{obs} = \frac{\nu_{com} + 1}{\nu_{com} + 3}\nu_{com}(1 - \frac{B + B/m}{m})$, $\nu_{com}$ is the hypothetical complete sample degrees of freedom, and $\nu_{old} = \frac{m - 1}{(m + 1/m)^2}$ [22].

Rubin’s rules were developed under the assumption of normality, so if our statistic in mind is not asymptotically normally distributed, then we need to transform it towards normality before pooling. There have been some research about how to pool non-normal quantities, but current research shows poor results and power when doing so [23]. Using Rubin’s rules, we now have a powerful framework to get a single, valid estimate from multiply imputed data.

It should be noted that while Rubin’s rules are the most popular method to combine MI estimates, there is another way to work with the multiply imputed data. This method is colloquially called the stacked method. For the stacked method, we take all of our imputed data and stack them one on top of each other to get one huge dataset of size $(m \times i)$ rows and $j$ columns. Under the stacked method, unbiased estimates of quantities of interest can be produced, but the estimates of variance will be too small (since we are artificially increasing the sample size) [1]. Thus, the stacked method is a poor choice for running any hypothesis tests or quantifying uncertainty. It is not useless though. The stacked method is useful when we want to analyze just one plot instead of $m$ for model checking. As well, the stacked method may be
useful in situations where we partition categorical data on an imputed variable and then look at the percentage in each category. Under the averaging portion of Rubin’s rules, we are not guaranteed that the percentages will sum to unity, but under the stacked method we are.

2.2 Survival Analysis

Now that we have the multiple imputation datasets created, we may run our analysis on each of them. Since the goal of this paper is to analyze cancer survival data, it naturally follows that the models we would like to run are survival models. As a general rule of thumb, we should run our desired analyses on the original available case data to get the available case estimates, as well as to get an idea of what to expect and to check if the model assumptions are met. Following Rubin’s rules, we run the individual analyses on each of the $m$ datasets, and then pool our results. In this section we will discuss each type of survival analysis and how to use them in the MI setting, as well as the issues associated with them.

2.2.1 Kaplan-Meier Survival Curve

Analysis for the Kaplan-Meier estimate is quite simple in the non-MI setting, but special care should be taken in the MI setting. First, we need to clearly define what the groups and population are, and what constitutes an event of interest. A very common mistake that researchers make is to try to frame a competing risks problem as a Kaplan-Meier problem. We also need to be sure that we have non-informative censoring, that is, knowing that the individual is censored tells us nothing about their survival probability. Once we have checked all of these, we can compute the Kaplan-Meier curve on each of the $m$ datasets. For simplicity, in this section we assume
that the Kaplan-Meier curves are run on a dataset with only subjects who took either a treatment or a control. Now, we could pool these estimates, but that would be ill-advised because the Kaplan-Meier curve is not normally distributed. To get around this, it has been proposed by Marshall et. al to take the complimentary log-log transformation of the Kaplan-Meier estimates before pooling [23]. We can make this transformation, pool our results, and then back transform to get the pooled MI Kaplan-Meier estimate.

In the MI setting, an interesting situation may arise when the last event (and thus the range of survival time) differs between the imputed datasets. This is the result of a person with a long survival time being put in different groups via imputation. We can deal with this by either extending the last observed Kaplan-Meier estimate out until the last event time, truncating all of the imputed curves at the minimum time of last event, or using other methods to deal with this situation as described in reference [3]. In traditional analysis, we would not extend out the Kaplan-Meier curve out past the last event, but if we have wildly varying imputations, this might be a good option, so that we can make inference between curves and are not hampered by one poor imputed dataset. As well, we could use the stacked method to get the Kaplan-Meier estimates, but we must accept the fact that the variance at every time point will be too small. The decision of what to do is up to the researcher and depends on the nature of the problem.

2.2.2 Median Survival Time

Once the Kaplan-Meier curve has been estimated, one of the main tasks that clinicians are interested in is the median survival time of each group, which is the smallest time that the survival function for the group is less than 0.5. Since the true survival
function is unknown, the Kaplan-Meier estimate is used. The median is the preferred method of central tendency in survival analysis because often times the survival times are right skewed, making the mean a poor estimator of the truth. Finding the median in the MI case is quite simple, as it is the first time that the pooled MI Kaplan-Meier curve crosses below 0.5. We would also like to have the variance at the median. The first way to obtain it is to multiply impute the variance (i.e. make the variance the scientific estimand of interest), and then use Rubin’s rules to get the variance associated with each time point and then take the average as the variance at that time point. However, taking the mean and variance of the variance doesn’t make much sense, and under typical pooling of the Kaplan-Meier estimate, we already get a good estimate of the variance. A better solution for this issue is to derive the variance of the median by the “reflection method”. In this method, we first fit the MI Kaplan Meier curve, and then construct a 95% confidence interval for all time points using the total variance obtained from Rubin’s rules pooling. The median is defined as the first time when the pooled MI curve crosses 0.5, and the lower and upper 95% confidence interval for the median are the medians of the upper and lower confidence bands. This method is preferred because it uses the variance we actually have and is much more robust to poor imputations.

2.2.3 Log Rank Test

Now we have a pooled estimate of the true survival curve for each group. In the typical setting, we might want to look to see if these curves are similar to each other, so we can determine if the treatment really changes the survival function. We would do this with the log rank test under the regular setting. However, we should not be deceived. We have an MI pooled survival curve, which is not constructed in the
same way that a regular Kaplan-Meier curve is. Because of this, we cannot get the quantities that we would need to compute the log rank test. However, we can still get the MI pooled log rank test. To do so, we can do one of two things. The first is to run the log rank test on each of the MI datasets and then pool the results via Rubin’s rules. This is the logical way to do it, but under this scheme we will run into a multiple comparison problem. As well, Marshall shows that this method is unreliable and will not give the proper p-values [23]. Another option is to run a Cox regression on just the treatment indicator and then compute the score test statistic, since this is equivalent to the log rank test under no tied failure times [3]. Under tied failure times, they are very similar to each other. From the Cox regression, we can obtain the score test for each of the datasets. We could pool the score test from each MI dataset, but we will once again run into problems with the actual pooling. We could also try to run the score test on the pooled MI Cox regression model, however, in order to do this, we need to know who is in the risk set. But the concept of a risk set doesn’t exist in the MI setting. Luckily, the Wald test is asymptotically equivalent to the score test, and the Wald test is very easy to obtain. So we can use the Wald test of the coefficient from the Cox model as a proxy for the log rank test. In this way, we get a statistic that calculates what we want, while still making sense in the MI context.

2.2.4 Cox Proportional Hazards Model

We would now like to investigate the hazard ratio of different baseline covariates and treatments via the Cox proportional hazards model. The overall goal will be to fit a Cox model with baseline covariates, check to see if it passes the proportional hazards assumption, and then add in the treatment variables to see how they affect
the hazard. It is known that the Cox regression coefficients are normally distributed, so there is no issue in pooling, but we do need to be careful about checking the proportional hazards assumption. The very first thing that we need to do is check to check the available case model to assess if we have proportional hazards. If one of the covariates truly is dependent on time, adding imputed data isn’t going to change that, so checking the available case analysis is a good sanity check. The way we go about checking to make sure that we have proportional hazards is looking to see if the Schoenfeld residuals are uncorrelated with time for each covariate in the Cox model [24]. The Schoenfeld residuals are tedious to explain and derive, and add no value to this thesis; however knowing that they are partial residuals that are formulated to be independent of time should suffice to understand this paper. The most common way to determine proportional hazards is to plot the spline fit (often cubic) to the residuals along with the 95% confidence intervals, and see if any straight line could pass through the bounds. Because the residuals are independent of time, a straight line over time signifies that the hazards are proportional [24]. There isn’t an official name for this method, but the straight edge method seems to be a fitting name since you can check it by placing a straight edge between the confidence bands. If this is the case, then we say that that the covariate in question does not depend on time, and follows the proportional hazards assumption. Another popular method to check for proportional hazards is to use a chi square test of independence between the Schoenfeld residuals and time.

If the proportional hazards assumption for a covariate is not met, then we can remedy it by entering that covariate into the Cox model as a time-covariate interaction term. This is beyond the scope of this thesis, but is something that could certainly appear in practice.
We have discussed how to check the proportional hazards assumption in the available case scheme, but how can we do this in the MI setting? We can take our imputed data and fit a Cox model on each of the $m$ datasets, and pool them easily. But how is the best way to check the proportional hazards assumption? We can go about this in a few different ways. The first is to check the proportional hazards assumptions on each individual MI dataset. This may prove to be an arduous task especially with large $m$ and a large number of covariates in the model. Alternatively, we could superimpose all of the spline fits on one plot, and see how the shape and general trend compare to the available case analysis. We can also use the stack data to get just one set of plots, but the straight edge method will not work here since the errors are too low.

Once we have verified that the model follows the proportional hazard assumption, we may trust its results. We can now add in our treatment covariates, and analyze it to see how they affect the hazards.

2.3 Causal Analysis

Now that we have laid down the theory for analyzing the survival section for clinical relevance, we can move on to the causal analysis part. Viewing the analyses with a causal lens is important, because as of now with only survival analysis, we cannot be sure if the differences in treatments are actually due to the treatment or to some differences in the groups before they even received the treatment. While there is a lot of preparatory work that goes into the theory of it, the results that can be obtained using causal analysis framework and propensity scores is much stronger and appealing than conventional analysis. Although no statistical method will give us a causal relation, the results from causal analysis will be much more similar to the
results we would have obtained from an RCT, and analysis on the true treatment
effect can be more easily studied.

Propensity score methods are an easy to understand yet powerful tool to help
implement Rubin’s causal model. The use of propensity scores justified in Rosenbaum
and Rubin’s 1983 paper [9]. Our overall goal is to estimate the average treatment
effect in a setting where the initial study was not an RCT. We will use the propensity
scores to balance the groups and remove the effect of confounders, so that the data
seems more like an RCT.

Before we even begin using propensity scores, we should have in mind what es-
timand we wish to estimate (the ATE or the ATT). It should be noted that while
the ATE and ATT deal with means, the definition can be slightly modified so that it
refers to the relative change in the hazard of the occurrence of the outcome between
the treatment groups [25]. The choice of estimands should be done by addressing the
problem and discussing the implications of each with subject matter experts. Once
we have this, we can start out with the propensity score methods.

2.3.1 Selecting the Method

We will need to make many decisions along the way, both in how to use the propensity
scores, and how to combine them with the MI data. There are four main uses of
propensity score in the literature: matching, stratification, weighting, and covariate
adjustment [25]. The goal is to balance the treatment and control groups, such that
the only difference between the groups is due to the treatment received, and not any
underlying factor. All of these methods will help us to examine the average treatment
effect, but each goes about it in a different way. Covariate adjustment and matching
have fallen out of favor in the literature recently, but weighting and stratification
remain very popular [25]. We will be using weighting in our real data analysis, so the main focus will be on that, but the methods discussed will work with any propensity score method. Whatever method is chosen will need to be run on each of the MI datasets.

Since the stack method will not work for propensity score analysis (there will be a falsely inflated sample size), we must decide how to use propensity scores on the multiply imputed data. Two methods are described in Mitra and Reiter about how use propensity scores in the MI setting [26]. In both methods, the propensity scores are first computed for each MI dataset, as we would normally do in the analysis part of the MI process. However, how the two methods use the propensity scores are different. In the first method, known as the “within” method, the propensity score method is done within each MI dataset and then pooled. For example, if we wanted to find the ATE, we would estimate the ATE in each dataset, and then pool via Rubin’s rules. The other method, known as the “across” method, takes the \( m \) estimates of each individuals propensity scores between the MI datasets, and then averages them so that every subject has one averaged propensity score. Once the global averaged propensity scores are estimated, then the propensity score method is used in each dataset (using the global list), the ATE is estimated on each dataset, and then pooled via Rubin’s rules. Both methods have their pros and cons, and are appropriate for different scenarios.

2.3.2 Obtaining the Propensity Score

Now that we have discussed how to use propensity score methods in the MI setting, let’s discuss how to actually get the propensity scores for each MI dataset. From now on, propensity score weighting will be the only method discussed, because that is
what will be used in the application section. However, the framework will still work for other types of propensity score methods.

Different propensity scores will be obtained according to what pretreatment covariates we use in the propensity score model, so we need to be sure that model is fit with clinically relevant and meaningful predictors that are believed to cause differences between the groups. Recall that our overarching goal is to account for any confounding factor, and to try to make the no unmeasured confounders assumption more reasonable. Basically, we would like to control for everything that could be different between the two groups. There has been significant debate among statisticians about how to set up these models, by either throwing in every possible variable into it, or only include covariates known to affect treatment selection. I don’t plan to settle this debate, but I do believe that the user should account for everything that is believed to be different between the two groups in question, in order to make the no unmeasured confounders assumption more plausible.

Obtaining the propensity scoring using logistic regression is simple and has been historically used, but with newer machine learning methods, we are able to get better propensity score weights that induce more balance (which will be talked about next). For single analysis, logistic regression would be preferred due to its simplicity and power, but in the MI setting, the model that produces correct propensity scores for one dataset might not fit well for another one. That is why machine learning methods are preferred. In recent years, boosting has become very popular method to compute propensity scores. In boosting, a simple piecewise linear function is fit to the data, and after every iteration, a new piecewise linear function is fit to the previous models residuals. When boosting, the propensity scores can be selected in a way to achieve optimal balance between the groups, while also remaining simple and theoretically
sound [27].

### 2.3.3 Verifying Balance

The goal of weighting is to create a pseudo-sample that is balanced, by up weighting samples that look like treatment cases, and down weighting those who do not. The formula for each weight can be concisely given as

\[ w_i = \frac{T_i}{\hat{e}_i(x)} + \frac{1-T_i}{(1-\hat{e}_i(x))}, \]

recalling that \( T_i \) is the treatment indicator, so only one of these terms is ever not 0. Two methods have been suggested to check for balance. The first is known as standardized bias. For each pretreatment covariate we wish to balance, we see how similar the cases and controls are by observing

\[ \left| \bar{X}_{k1} - \bar{X}_{k0} \right| / \hat{\sigma}_k, \]

where the barred \( X \)’s denote the propensity score weighted means of the covariate in question in the treatment and control groups, and the \( \hat{\sigma} \) is the unweighted standard deviation of both groups together. Typically, standardized bias below .2 or .25 indicates good balance, although this number is subjective [27]. Another common method is the Kolmogorov-Smirnov (KS) test of distributional equality. This nonparametric test assumes the null hypothesis that the distribution of the two populations are no different. To get the KS statistic, the Empirical Cumulative Distribution Function (ECDF) is computed for the two (weighted) groups, and then the maximum distance between the two ECDF’s is calculated. Its p-value is found via the permutation test [27]. Both of these methods offer us tools to assess balance in the data when weighted by the propensity scores. We can use the tools to our advantage alongside of a boosting algorithm to get propensity scores that offer the best balance. Although we will need to decide which metric to assess balance on, controlling for one usually leads to controlling of the other.

Once we have obtained our optimal propensity scores for each MI dataset, we weight the data by them. As well as checking that we truly have achieved balance,
we also need to look at the distribution of the propensity scores. We would like to see some overlap between the treatment and control propensity scores. Overlap indicates that subjects in both groups are similar to each other, and can be compared. If the propensity scores don’t have any common support, then we have not properly balanced. We should also be sure that all of the propensity scores are bound between zero and one. If a subject has a propensity score that is either one or zero, then they will always be or never be treated, and estimating the counterfactual will be impossible.

Once we have our propensity scores, we need to go about checking the treatment effect. We have no guarantee that the model we set for our propensity score is correct, so many authors advocate including the covariates in the propensity score model in the analysis of the treatment effect (this is known as a doubly robust method) [12].

Now that the theory is set up, we may use it on the MI data. And now we may interpret the results with a causal lens, even though the data may be observational. We will be using the “within” method, so for each MI dataset, we compute the treatment effect from the propensity score weighted data. While we could check the treatment effect in terms of time difference in survival between the treatments, this doesn’t work very well, because we have censored data. The better option is to observe the average treatment effect by looking at the relative change in the hazard of the occurrence of the outcome between the treatment groups. Checking the hazard makes use of the fact that we have censoring in the data [25]. We may then combine the estimates via Rubin’s rules to get the MI estimate of the average treatment effect and its variance.
Chapter 3

Application

3.1 Data Explanation

Now that the theory is in place, we can apply it to real data. The dataset that I chose to analyze is a dataset from MD Anderson Cancer Center, with permission from Dr. Bugano, Dr. Ibrahim, and Dr. Hess. The IRB protocol is RCR03-0931. This dataset has historical records of 1514 MD Anderson patients who have had breast cancer that has metastasized to the brain from October 2009 to December 2012. The data is not from an RCT, rather it is from a retrospective observational study of patient records, where oncologists chose what treatments to give. The word metastases is often shortened in speech and in paper to the word “mets” because it is easier to say.

The dataset consists of 111 covariates, with missingness ranging from 0 to 99%. Some predictors are metadata, and rare tests, so they will not be considered. Ignoring these, the missingness in the useful data ranges from 0 to 65%. Included in these are 90 different covariates, a few different treatments, as well as survival endpoints (which are all observed). The data can be broken down into a few broad categories, as can be seen in table 3.1. There are too many covariates to completely explain here, but I’ve listed the ones relevant to our models in table 3.2.

To get a feel for how the data is missing, in figure 3.1 we see a plot of the missingness in the data. The data is organized in the same fashion as the categories in table 3.1. There are some covariates such as genetic tests and clinical observations
<table>
<thead>
<tr>
<th>Type of Data</th>
<th>Examples</th>
</tr>
</thead>
<tbody>
<tr>
<td>Subject</td>
<td>Age range, race, date of birth</td>
</tr>
<tr>
<td>Breast Cancer</td>
<td>TNM staging, histology, receptor status</td>
</tr>
<tr>
<td>Pre brain mets</td>
<td>Treatment types</td>
</tr>
<tr>
<td>Post brain mets clinical</td>
<td>Seizures, headache, nausea</td>
</tr>
<tr>
<td>Post brain mets</td>
<td>Treatment type, type of brain mets</td>
</tr>
<tr>
<td>Survival data</td>
<td>Survival time after brain mets, censoring indicator</td>
</tr>
</tbody>
</table>

Table 3.1: Data categories and examples

<table>
<thead>
<tr>
<th>Name</th>
<th>Percent</th>
<th>Missing</th>
<th>Meaning</th>
</tr>
</thead>
<tbody>
<tr>
<td>capeothno</td>
<td>18%</td>
<td></td>
<td>Indicator: Capecitabine, other, or no chemotherapeutic treatment. Treatment variable 1</td>
</tr>
<tr>
<td>lapatrasno</td>
<td>18%</td>
<td></td>
<td>Indicator: Lapatinib, Trastuzumab, or no HER2-directed treatment. Treatment variable 2</td>
</tr>
<tr>
<td>controlled</td>
<td>12%</td>
<td></td>
<td>Indicator: Systemic disease (extracranial) not progressing at the time of diagnosis of brain mets</td>
</tr>
<tr>
<td>hrher2</td>
<td>5%</td>
<td></td>
<td>Categorical: The hormonal receptor (er, pr) and HER2 receptor status of the subject</td>
</tr>
<tr>
<td>braintype</td>
<td>4%</td>
<td></td>
<td>Categorical: Single, multiple, Leptomeningeal disease</td>
</tr>
<tr>
<td>timedx</td>
<td>1%</td>
<td></td>
<td>Time (years) from breast cancer diagnosis to brain mets</td>
</tr>
<tr>
<td>site5</td>
<td>1%</td>
<td></td>
<td>Indicator: First metastasis was to brain</td>
</tr>
<tr>
<td>race2</td>
<td>0%</td>
<td></td>
<td>Categorical: White, Black, Hispanic, Other</td>
</tr>
<tr>
<td>priorn</td>
<td>0%</td>
<td></td>
<td>Number of prior treatments in metastatic setting before brain mets</td>
</tr>
<tr>
<td>os</td>
<td>0%</td>
<td></td>
<td>Overall survival (months)</td>
</tr>
<tr>
<td>dead</td>
<td>0%</td>
<td></td>
<td>Indicator: Censoring indicator</td>
</tr>
<tr>
<td>agebrainmet</td>
<td>0%</td>
<td></td>
<td>Age at time of brain mets</td>
</tr>
</tbody>
</table>

Table 3.2: Table of important covariates to be used in the analysis
that are nearly never collected (the nearly solid white lines and blocks), but overall, there seems to be no real pattern in the way the data is missing.

Figure 3.1: Visualization of missingness in the cancer dataset

Along the horizontal axis are the subjects, and the vertical axis are the covariates. Black denotes observed values whereas white is missing. The covariates with the highest missingness are genetic measures, as well as some clinical assessments.

This data is exemplary for demonstrating thesis ideas because it is a large retrospective study (pulled from a database), survival amenable, has missingness that is
Our first step is to clearly define what questions we would like answered. We will consider two separate questions in this analysis. In the first, we will explore the treatment effect (in terms of survival) of Capecitabine (a chemotherapeutic agent) versus other chemotherapeutic agents versus no treatment. In the second, we will look at the effect of two HER2-directed drugs (Lapatinib versus Trastuzumab) versus no HER2-directed drugs in a subset of the patients who are HER2 positive (HER2+).

It isn’t vital to understand the entirety of cancer and its treatments for understanding this analysis, but the interested reader may want to look at appendix A.2 for a very basic overview of breast cancer and how different cancer drugs work. For a much more detailed analysis and other clinically relevant questions, see the upcoming paper by Bugano, Hess, and Berliner. This is the project that this thesis was forked off of.

### 3.2 Imputation

Our first step in analyzing the data is to impute the missing data. This is a challenging task, because of the attention and care that needs to be given to imputing about 90 covariates with missing data. Although we will not be using all 90 covariates, it is important that we impute them, and do so properly. We need all of the values imputed because: they have the potential to be useful as predictors for other covariates, they might be something we are actually analyzing (now or later), we have spent the money to collect the data, and it strengthens the MAR assumption. As well, it is my opinion (and probably a consensus among applied statisticians) that is better to have too many covariates than not enough. After all, variable selection can be performed
if there are too many covariates.

Our data is quite high dimensional, and there are a many binary and categorical variables as well as a handful of strictly non-negative covariates, thus JM imputation seems inappropriate. Instead, FCS models seem better suited. We will be using the R package mice [15] because it is easy to use yet powerful. There are other software implementations in different languages (such as PROC MI in SAS, ICE in Stata, and package mi in R), but I found mice to be the most flexible while also being powerful and easy to use.

The first task we need to do is to assess the missing data mechanism. As we have discussed before, there is no formal statistical test to determine what the mechanism is. It is very unlikely that the data is MCAR (which we typically associate with random/accidental deletion), so it is between MAR and MNAR. We have so many different covariates, and it could reasonably be assumed that the missing data we have could be explained by the type of disease, its stage, the subject’s age, their standardized assessment, and their survival time, among other things which we have collected. So it would be reasonable to assume that the missing data mechanism is MAR, and thus imputation can be confidently used.

Now that the missing data mechanism has been assessed, the imputations need to be set up. For each covariate with missingness, we need to decide the form of the imputation model that will be used for imputation, and what predictors will be used in it. Most of the covariates that needed imputation were either binary or categorical, so the most popular model chosen were logistic regression, multinomial logit regression, or predictive mean matching. The method that was most appropriate for each situation was chosen. The continuous variables were often selected via regression or predictive mean matching. As for the predictors in each imputation model, nearly
every reasonable predictor for each missing covariate is used. This was done to bolster
the MAR claim, and avoid variable selection. Van Buuren proposes measures called
influx and outflux to determine how worthy and connected each covariate will be as a
predictor [1]. This information was used to remove 11 covariates that were very poor
for prediction.

Once the model and predictor choices were made, the imputations were run and
tuned, and checked by trial and error. This took a considerable amount of time, be-
cause after every change made, the algorithm needed to be rerun and the convergence
and imputations needed to be assessed. As well, changes in model specification were
rarely localized to that variable, as they often affected others.

It took about three weeks to set up and check the models. This was because
the number of covariates was large, and checking the imputations after a change was
time consuming. It would not take this long for a smaller dataset. Creating valid
imputations is a skill that lies somewhere between an art and a science, so it takes
the theory to know what to do, and trial and error to see if you’ve done it correctly.

For the final MI dataset, it was decided to impute $m = 50$ datasets and 40
iterations for each. Research by White et. al says that the number of imputed
datasets $m$ should be at least 100 times the percentage of incomplete cases (for the
analysis at hand) [20]. The data used in our analyses had about 30% missingness,
so imputing 50 datasets was the chosen number. Mice generally converges quickly
(within 5 or 10 iterations), but by setting the number of iterations so high (40), we
are guaranteeing that we are drawing from the correct distribution.

After the final imputation model for each covariate with missingness has been set
up, we need to run it and save the results. For 50 datasets, 40 iterations, the algorithm
runs in about 4 hours, and for 50 datasets with 100 iterations, it took 11.5 hours on
a computer with 4 GB of RAM and 4 cores. While this seems like a long time, this process only needs to be done once and requires no human interaction while running, so it can be run overnight and then never need to be touched again. The imputations were run for 100 iterations to see how the run time scaled, as well as to check how the chains behaved and to see how the analyses differed. The results between 50 and 100 iterations were very similar. As well, there is hardly any confidence to be gained going from 50 to 100, and having such large objects in memory can be harder to work with. This is why 50 MI datasets, with 40 iterations for each was chosen.

We need to check our final imputations for convergence, reliability, and validity. Convergence is assessed by looking at the trace plots of the imputed value by iteration for each covariate we imputed. According to van Buuren “the different streams should be freely intermingled with each other, without showing any definite trends. Convergence is diagnosed when the variance between different sequences is no larger than the variance with each individual sequence” [15]. This may be hard to visualize all at one time because for each variable, there will be 50 times the number of missing data values for that covariate, so many authors suggest checking the plots of the chain mean and standard deviation by iteration instead. For continues variables, the chains are checked to see how the variance between and within changes at each iteration, as well as to ensure the chains show no pattern.

Diagnosing convergence for binary and categorical variables is a bit tricky, because the mean of a categorical variable is nonsensical, but we can get a good idea of convergence by looking at if the variance remains constant. And for binary variables, knowing how the groups are coded and looking at where the means of the chains are can give us an idea of healthy convergence. For example, in the cancer dataset, the variable HER2 is coded as 1 for being HER2 negative and 2 for positive. In the
available cases, the split between being HER2 negative and positive is about 60 to 40. Thus, if we were to look at the average of the chains groups, we would expect it to be around 1.4. Seeing something radically different than this (perhaps a mean of 1.9) might suggest the imputation was done wrong, because the group percentages are not near what they should be. We can assess the convergence of the binary variable also by checking how its variance changes by iteration. Large changes from groups by iteration will be noted as large changes in the variance plots, whereas staying constant indicates that the draws are remaining relatively stable.

Since there are 90 plots to check, they cannot all be shown in this paper. However, each of them have been checked. Some interesting ones may be seen in figure 3.2 and 3.3. Looking at these plots, convergence certainly seems to be the case. Other authors suggest using a more formal statistical tests such as $\hat{R}$ scale reduction factor, but since most of our interesting variables are categorical, this does not make much sense.

Once the convergence is diagnosed, the validity of the imputations needs to be inspected. Diagnostic plots and tables are viewed to ensure that the imputed data are realistic. Common plots include density plots of each covariate compared to the complete cases, as well as bivariate scatterplots for imputed variables. For categorical variables, tables and other group checks may be used. A few of the plots have been replicated here in figures 3.4, 3.5, 3.6. Once again, all of the plots cannot be displayed in this paper, but some important ones are recreated. As we can see, not all of the imputed data looks like the real data, but for the majority of the plots, the imputed data seem reasonable and look like they could have been real data had they not been missing.

Before we move on to the analyses, let’s have a look at the breakdown of the MI data. Using the stack method, table 3.3 is created. In this table, we can see how
Figure 3.2: Selected convergence plots of continuous variables

Figure 3.3: Selected convergence plots of binary variables
Figure 3.4: Selected density plots of continuous imputed variables

Blue indicates the original density, whereas the red are the imputed dataset densities. The spike in the second plot at zero is due to smaller values being imputed to zero.

the MI data compares to the available case data, broken down by if the subject had any systemic therapy for the brain mets. Systemic therapy refers to any therapy where treatments are given that “spread throughout the body to treat cancer cells wherever they may be” [28]. Both chemotherapy and HER2-directed therapies are systemic therapies. Systemic therapy does not include treatments such as resection or targeted radiation.
Figure 3.5: Selected box and whisker plots of continuous imputed variables

Blue indicates the original box and whisker plot, whereas the red are the imputed dataset box and whisker plots.

Figure 3.6: Selected histograms of the ratio of imputed variables

Ratio of Cape/Other
AC ratio = 0.415

Ratio of lapat/trastuz
AC ratio = 0.561
### Table 3.3: Characteristics of AC data versus MI data

<table>
<thead>
<tr>
<th></th>
<th></th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (mean, sd)</td>
<td>51.4(10.8)</td>
<td>51.2(10.9)</td>
<td>52.7(11.9)</td>
<td>52.9(11.4)</td>
</tr>
<tr>
<td>Breast Cancer subtype</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR+/HER2-</td>
<td>27%</td>
<td>31%</td>
<td>28%</td>
<td>33%</td>
</tr>
<tr>
<td>HR+/HER2+</td>
<td>19%</td>
<td>18%</td>
<td>12%</td>
<td>13%</td>
</tr>
<tr>
<td>HR-/HER2+</td>
<td>22%</td>
<td>20%</td>
<td>15%</td>
<td>12%</td>
</tr>
<tr>
<td>Triple negative</td>
<td>32%</td>
<td>32%</td>
<td>45%</td>
<td>42%</td>
</tr>
<tr>
<td>Prior Therapies for stage 4</td>
<td>1(0-3)</td>
<td>2(0-4)</td>
<td>2(0-4)</td>
<td>2(0-4)</td>
</tr>
<tr>
<td>Single Brain Lesion</td>
<td>25%</td>
<td>23%</td>
<td>23%</td>
<td>20%</td>
</tr>
<tr>
<td>Controlled extra-cranial</td>
<td>40%</td>
<td>40%</td>
<td>35%</td>
<td>36%</td>
</tr>
<tr>
<td>ECOG 0-1</td>
<td>84%</td>
<td>70%</td>
<td>53%</td>
<td>40%</td>
</tr>
<tr>
<td>Local Therapy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Resection Alone</td>
<td>5%</td>
<td>5%</td>
<td>9%</td>
<td>7%</td>
</tr>
<tr>
<td>SBRT Alone</td>
<td>13%</td>
<td>12%</td>
<td>9%</td>
<td>8%</td>
</tr>
<tr>
<td>WBRT</td>
<td>60%</td>
<td>59%</td>
<td>52%</td>
<td>53%</td>
</tr>
<tr>
<td>Resection/SBRT+WBRT</td>
<td>12%</td>
<td>14%</td>
<td>10%</td>
<td>8%</td>
</tr>
<tr>
<td>No local</td>
<td>10%</td>
<td>10%</td>
<td>20%</td>
<td>23%</td>
</tr>
</tbody>
</table>

#### 3.3 Survival Analysis

Now that the $m = 50$ datasets are imputed, we are ready to run our models on them. Before we begin though, we should check all of the models we will run on the available cases to make sure that the model assumptions are met, and to get an idea of the importance of each part of the model. The available case models (Kaplan-Meier, Cox) were run before doing multiple imputation, and all of the model assumptions were met. You can see the results of the AC analyses, alongside the MI values throughout
Before we begin the analyses though, we should discuss the analyses at hand. The endpoint we are looking at is overall survival (i.e. freedom from death of any cause). It should be noted that in all of our survival analyses, we will be doing a landmark analysis. Landmark analysis means that we don’t start the analysis at time 0, rather, we start it at a time later than 0. Since the brain mets treatment data was determined after the diagnosis of the brain met, it is not appropriate to use them as baseline covariates in the analyses. Doing a landmark analysis at a time when the vast majority of patients would have had their brain mets treatment choices started allows us to escape this problem. After speaking with cancer experts (Dr. Bugano and Dr. Ibrahim), this landmark time was determined to be 2 months. By doing a landmark analysis at 2 months, we are able to use the treatments as baseline covariates.

The first models that we will check in the MI setting are the Kaplan-Meier curves. Non-informative censoring seems to be a valid assumption, as knowing the censoring status seems to provide no information about the censoring time. The pooled KM estimate was found using Rubin’s rules, but under a complimentary log-log transform to get the survival curves towards normality [23]. The median and confidence interval about it was computed as the median of the upper and lower confidence bands.

For the comparison of the chemotherapeutic drugs, the KM curves can be seen in figure 3.7. The available case and MI analyses look similar, but the MI data seems to give a lower median survival time for the chemotherapeutic drugs. For not taking any chemotherapeutic drugs though, the median increased.

For the HER2-directed drugs, the KM curve can be seen in figure 3.8. The available case analysis shows that Lapatinib and Trastuzumab are quite close to each other
in terms of survival, while having no HER2-directed treatment is much lower. Once again, the MI analyses give lower values for the median survival time.

The Kaplan-Meier curves for both questions seem to show the same thing. As compared to the available case analysis, the estimates of survival are a little pessimistic for the treatments, and a little more optimistic for the no treatment group. This is likely due to the fact that a larger proportion of the missing treatments were assigned to no treatment (which echoes the data), causing their survival to go up. As well, the missingness in treatment for those who took chemotherapy and HER2-directed drugs was much higher at early overall survival times than for later times.

Now that we have a visual of the curves, we would like to see if there is actually a difference between them. Although visually, we can see that in both cases, no treatment seems to be much worse for survival than treatment, we need to formalize
To do so, the log rank test needs to be run on them. Recall that we are not able to get the exact log rank test because the quantities needed to calculate them don’t exist in the MI setting. As discussed in the methods section, our best option is to get an approximation to the log rank test by using the Wald test on the Cox regression on treatment membership, and use that value as a proxy for the log rank test since they are asymptotically equivalent.

The results for the overall test and for each comparison can be seen in table 3.4 and 3.5. The AC and MI results are quite similar. For Capecitabine vs other chemotherapeutic drugs, we see a relatively high p-value. Depending on the acceptable rate of significance, different conclusions might be drawn between the two analyses. In this study, the level is $\alpha = .05$, so changing conclusions is not an issue, however, since we are doing multiple comparisons, it may be prudent to use a Bonferroni correction for
multiple testing. For the HER2-directed drugs, there certainly seems to be a difference between the treatments and not having any, but there is no evidence that either of the treatments is better than the other.

<table>
<thead>
<tr>
<th></th>
<th>Chemo</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
</tr>
<tr>
<td>cape/other/none</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>cape/other</td>
<td>0.0321</td>
</tr>
<tr>
<td>cape/none</td>
<td>0.00039</td>
</tr>
<tr>
<td>other/none</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Table 3.4 : Chemotherapeutic drugs log rank tests

<table>
<thead>
<tr>
<th></th>
<th>HER2</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC</td>
</tr>
<tr>
<td>Lapat/Trastuz/none</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Lapat/Trastuz</td>
<td>.87</td>
</tr>
<tr>
<td>Lapta/none</td>
<td>.00017</td>
</tr>
<tr>
<td>Trastuz/none</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Table 3.5 : HER2-directed drugs log rank tests

Now that we have estimate of the survival curve, we may set up a model to observe how changes in some baseline covariates and the treatments change the hazard. We will do this with the Cox Proportional Hazards model. Once we have a baseline model fit and the assumptions met, we can add our treatment variable to see how this affects
the hazard. Speaking with the clinicians, they determined that the covariates listed in table 3.2 were clinically relevant for the baseline model.

We need to make sure that the proportional hazards assumption is met in the available case model to determine if the use of the Cox model is justified. To check, we visually inspect the spline fit to the Schoenfeld residuals over time (figure 3.9). In the available cases, the assumption of proportional hazards over time seems reasonable, as a straight line could reasonably be fit between the 95% confidence bands. A chi-square test of correlation also confirms this.

Figure 3.9: AC Schoenfeld residuals over time

Now, to check if we have proportional hazards in the MI data, there are two
options. The first is to fit a Cox model on the stacked data, but this will not give us accurate confidence bands. A better option is to look at the Schoenfeld residuals plot for each MI dataset individually. However this may be tedious. We can get the same result if we collect the spline fits from each MI dataset, and then superimpose them onto one plot, and assess the shape. This is what is done for the MI data, as can be seen in figure 3.10. The shapes are very similar to the available cases, so it is reasonable to assume that the proportional hazards assumption holds on the MI data.

Figure 3.10: MI Schoenfeld residuals over time

Now that the proportional hazards assumption is met, we can run the Cox model to obtain the hazard ratios for the factors we want to control for at baseline. A table of the AC and MI analyses can be seen in table 3.6.

We may then add in our treatment variable to see how they affect the hazard
Table 3.6: AC and MI baseline Cox model

<table>
<thead>
<tr>
<th>Variable</th>
<th>Contrast</th>
<th>HR</th>
<th>95% CI</th>
<th>pvalue</th>
<th>HR</th>
<th>95% CI</th>
<th>pvalue (t test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>HR/HER2</td>
<td>-/+ vs. -/-</td>
<td>0.57</td>
<td>(0.46,0.71)</td>
<td>&lt;0.0001</td>
<td>0.59</td>
<td>(0.48,0.72)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>+/- vs. -/-</td>
<td>0.66</td>
<td>(0.54,0.81)</td>
<td>&lt;0.0001</td>
<td>0.63</td>
<td>(0.52,0.76)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>+/- vs. -/-</td>
<td>0.4</td>
<td>(0.31,0.50)</td>
<td>&lt;0.0001</td>
<td>0.4</td>
<td>(0.32,0.50)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Age</td>
<td>&gt;60 vs. &lt;60</td>
<td>1.37</td>
<td>(1.13,1.65)</td>
<td>0.0011</td>
<td>1.45</td>
<td>(1.22,1.72)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Dx to BM</td>
<td>&gt;6 vs. &lt;6</td>
<td>0.66</td>
<td>(0.54,0.82)</td>
<td>0.00013</td>
<td>0.71</td>
<td>(0.59,0.86)</td>
<td>0.0002</td>
</tr>
<tr>
<td>First DM</td>
<td>Brain vs. Oth</td>
<td>0.8</td>
<td>(0.66,0.97)</td>
<td>0.026</td>
<td>0.83</td>
<td>(0.70,0.99)</td>
<td>0.02</td>
</tr>
<tr>
<td>Race</td>
<td>Hisp. Vs. White</td>
<td>0.85</td>
<td>(0.68,1.07)</td>
<td>0.17</td>
<td>0.88</td>
<td>(0.71,1.08)</td>
<td>0.11</td>
</tr>
<tr>
<td></td>
<td>Black vs. White</td>
<td>1.31</td>
<td>(1.06,1.63)</td>
<td>0.014</td>
<td>1.25</td>
<td>(1.02,1.52)</td>
<td>0.015</td>
</tr>
<tr>
<td></td>
<td>Other vs. White</td>
<td>0.65</td>
<td>(0.40,1.04)</td>
<td>0.075</td>
<td>0.7</td>
<td>(0.45,1.07)</td>
<td>0.05</td>
</tr>
<tr>
<td># prior Rx</td>
<td>&gt;2 vs. 0-2</td>
<td>1.58</td>
<td>(1.31,1.91)</td>
<td>&lt;0.0001</td>
<td>1.53</td>
<td>(1.29,1.82)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>BM type</td>
<td>Mult. Vs. Single</td>
<td>1.45</td>
<td>(1.20,1.76)</td>
<td>&lt;0.0001</td>
<td>1.48</td>
<td>(1.24,1.76)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td></td>
<td>LMD vs. Single</td>
<td>1.6</td>
<td>(1.21,2.13)</td>
<td>0.001</td>
<td>1.58</td>
<td>(1.25,2.00)</td>
<td>&lt;0.0001</td>
</tr>
<tr>
<td>Sys. Cont.</td>
<td>Yes vs. No</td>
<td>0.71</td>
<td>(0.61,0.83)</td>
<td>&lt;0.0001</td>
<td>0.73</td>
<td>(0.63,0.85)</td>
<td>&lt;0.0001</td>
</tr>
</tbody>
</table>

The analysis for the chemotherapeutic in the MI setting is easy, since it applies to all subjects, but the model for the HER2-directed drugs is more difficult, since it is only for patients who are HER2 positive. Both HER2 status and the treatment were imputed. Because of this, special care needed to be taken when the data was
subsetted in each MI dataset. There was some variation between the sample size in each analysis (ranging from 391 to 415), but this was to be expected.

As it has been posited before, the use of chemotherapeutic and HER2-directed drugs seem to greatly reduce the hazard ratio of death in comparison with not taking any treatment. The effect of other covariates in the presence of these drugs seems to change though.

<table>
<thead>
<tr>
<th>Variable</th>
<th>Contrast</th>
<th>HR</th>
<th>95% CI</th>
<th>p-value</th>
<th>HR</th>
<th>95% CI</th>
<th>p-value</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>AC n=745</td>
<td></td>
<td></td>
<td></td>
<td>MI n= 1021</td>
<td></td>
<td></td>
</tr>
<tr>
<td>HR/HER2</td>
<td>-/+ vs. -/-</td>
<td>0.62</td>
<td>(0.49,0.79)</td>
<td>&lt;.0001</td>
<td>0.63</td>
<td>(0.51,0.77)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td></td>
<td>+/- vs. -/-</td>
<td>0.65</td>
<td>(0.53,0.81)</td>
<td>0.0011</td>
<td>0.64</td>
<td>(0.53,0.78)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td></td>
<td>++ vs. -/-</td>
<td>0.41</td>
<td>(0.31,0.53)</td>
<td>&lt;.0001</td>
<td>0.42</td>
<td>(0.34,0.53)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Age</td>
<td>&gt;60 vs. &lt;60</td>
<td>1.34</td>
<td>(1.10,1.64)</td>
<td>0.0041</td>
<td>1.44</td>
<td>(1.21,1.72)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Dx to BM</td>
<td>&gt;6 vs. &lt;6</td>
<td>0.72</td>
<td>(0.58,0.90)</td>
<td>0.0032</td>
<td>0.71</td>
<td>(0.58,0.86)</td>
<td>0.00039</td>
</tr>
<tr>
<td>First DM</td>
<td>Brain vs. Oth</td>
<td>0.77</td>
<td>(0.63,0.95)</td>
<td>0.014</td>
<td>0.81</td>
<td>(0.68,0.96)</td>
<td>0.016</td>
</tr>
<tr>
<td>Race</td>
<td>Hisp. Vs. White</td>
<td>0.77</td>
<td>(0.61,0.98)</td>
<td>0.034</td>
<td>0.86</td>
<td>(0.69,1.06)</td>
<td>0.15</td>
</tr>
<tr>
<td></td>
<td>Black vs. White</td>
<td>1.29</td>
<td>(1.02,1.63)</td>
<td>0.032</td>
<td>1.23</td>
<td>(1.01,1.51)</td>
<td>0.043</td>
</tr>
<tr>
<td></td>
<td>Other vs. White</td>
<td>0.76</td>
<td>(0.47,1.25)</td>
<td>0.28</td>
<td>0.7</td>
<td>(0.45,1.08)</td>
<td>0.11</td>
</tr>
<tr>
<td># prior Rx</td>
<td>&gt;2 vs. 0-2</td>
<td>1.61</td>
<td>(1.32,1.98)</td>
<td>&lt;.0001</td>
<td>1.53</td>
<td>(1.28,1.82)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>BM type</td>
<td>Mult. Vs. Single</td>
<td>1.46</td>
<td>(1.20,1.78)</td>
<td>0.00017</td>
<td>1.51</td>
<td>(1.27,1.81)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td></td>
<td>LMD vs. Single</td>
<td>1.45</td>
<td>(1.04,2.03)</td>
<td>0.029</td>
<td>1.41</td>
<td>(1.11,1.80)</td>
<td>0.0049</td>
</tr>
<tr>
<td>Sys. Cont.</td>
<td>Yes vs. No</td>
<td>0.57</td>
<td>(0.48,0.68)</td>
<td>&lt;.0001</td>
<td>0.69</td>
<td>(0.59,0.80)</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Chemo</td>
<td>Cape. vs. none</td>
<td>0.69</td>
<td>(0.53,0.89)</td>
<td>0.0046</td>
<td>0.75</td>
<td>(0.60,0.95)</td>
<td>0.018</td>
</tr>
<tr>
<td></td>
<td>other vs. none</td>
<td>0.52</td>
<td>(0.42,0.65)</td>
<td>&lt;.0001</td>
<td>0.58</td>
<td>(0.47,0.71)</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

Table 3.7 : AC and MI Cox model with chemotherapeutic treatments
In both analyses, going from available case to MI interpretation, we see that the MI analyses are a little more pessimistic about the hazard ratio (i.e. the hazard ratios move closer to 1). However, the trend in reduction of hazard still holds. Other chemotherapeutics seem to reduce the hazard more than Capecitabine, and in HER2+ patients, Trastuzumab seems to decrease the hazard ever so slightly more than Lapatinib does.
3.4 Causal Analysis

Lastly, we will want to draw causal inference, and see what the average treatment effect of each drug is. We will do so by assessing the reduction in hazard via the Cox model. In the previous section, we fit a Cox model, but were unable to draw causal conclusions from it since the data was not obtained via an RCT. In this section, we aim to remove the effects of confounding so that we may treat it like an RCT. Recall that since we are in the MI setting, and that the treatment variables themselves are imputed, we will be using the “within” method for propensity scores, as described by Mitra and Reiter [26]. For each MI dataset, we will weight each observation by its inverse probability of treatment weight (IPTW), and then run a Cox regression to observe the treatment effects.

Before we even begin, we should ensure that the assumptions for Rubin’s causal model are met. For SUTVA, it is unlikely that a subject’s potential outcome will be affected by what treatment another subject receives. As for the no unmeasured confounders assumption, we aim to satisfy this by including many known confounders in the propensity score model.

In order to observe the results from a causal lens, we need to determine what type of treatment effect to look for. It should be noted that some authors use the term marginal to describe population level average effect, and conditional to describe the individual level average effect [29]. The goal of this study is to make inference about the population, not the individual, so the individual treatment effect is inappropriate. There are two options to choose from in what type of inference to do. There is the ATE, and the ATT. Since we have three comparisons for each comparison, and there is no clear cut accepted treatment for each, the ATT is not as useful as the ATE, thus we will chose to observe the ATE. Since the ATE will be obtained in each MI dataset
by IPTW weighted Cox regression, we are able to pool the results via Rubin’s rules to get the ATE as well as the uncertainty associated with it. In the end, we will get an estimate of the true causal relative change in hazard.

The idea for this part of the analysis is to use propensity score weighting to create a balanced sample for each MI dataset where the baseline covariates are not confounded with treatment assignment or result, and then treat it as if it was an RCT. Traditional methods to obtain the propensity score (like logistic regression) cannot be optimized for balance, however machine learning algorithms can be. The method chosen to fit the propensity scores are called Generalized Boosting Models (GBM). In this ensemble method, “the model consists of many simple regression trees iteratively combined to create an overall piecewise constant function. The iterative fitting algorithm begins with a single simple regression tree, and at each new iteration, another tree is added. The new tree is chosen to provide the best fit to the residuals of the model from the previous iteration” [27]. After each iteration in the GBM algorithm, the IPTW’s are applied to the data, and the balance of the covariates (according to the KS statistic) is measured. Standardized bias is more of a measure of central tendency of the groups, whereas the KS statistic is more about the distribution as the whole. Because of this, we will want to optimize on the KS statistic, although both measures should appear balanced after weighting. Once the GBM algorithm is run, the iteration that minimizes the KS statistic and maximizes its p-value for each variable while not overfitting the data is selected. We then take the propensity scores at that iteration as the propensity scores for that specific MI dataset.

In traditional propensity score analysis, there is only one treatment and control. However in our situation, there are actually three groups in each analysis. So we can no longer use methods tailored to two classes. We could fit a multinomial model
(that gives probability for three treatment classifications), but the theory behind
this is not as strong and easy to understand as with the binary case. However, if
we make treatment status an indicator (for example 1 if treatment is Capecitabine,
and 0 if it is other or none), then we may treat it as if it were binary. Because
we have three groups though, we will need to check the balance between all groups
(i.e. groups Capecitabine vs other, Capecitabine vs none, other vs none) to ensure
balance is achieved. Since we are summing three probabilities that are not from the
same model, we cannot be guaranteed that the probabilities will sum to unity. This
is not an issue though, because our primary interest lies in making sure the groups
are balanced, not in the sums of the probabilities [27].

We now have the propensity score model selected, and a plan about how to check
the balance, but now we need to ask what pretreatment covariates should we control
for. In speaking with Dr. Hess, we determined that there are many pretreatment
differences in the population that should be controlled for. So even though we wanted
to keep the propensity score model parsimonious, we were not able to. The covariates
we deemed to be important to balance before treatment include: breast cancer stage at
first diagnosis, race, type of breast cancer, breast cancer surgery type, first metastatic
site, number of prior treatments, ECOG score, localized brain mets treatment, type
of brain met, age at brain mets, and control of brain mets at diagnosis.

Once the propensity scores have been computed for each MI dataset, we need to
check that they are in fact valid. McCaffrey et Al. describe two conditions that need
to be checked, and graphical checks to do so. The first condition is to ensure that
all of the propensity scores are between 0 and 1. If any propensity score is 0 or 1,
then there is no chance that the subject looks like that of another group. If this is
the case, then the results will be poor, because the counterfactual framework and
propensity score analysis are not meant to handle cases like this [27]. All 50 plots for
the distribution of the propensity scores cannot be shown in this paper, but I show
the propensity scores from two of the MI datasets. In these plots (figure 3.11), we
see that the propensity scores are never exactly 0 or 1, and as well, the groups are
differentiated, yet still have common support.

![Propensity Score Plots](image)

Figure 3.11: Selected propensity score distribution checks

The next check is the check of no unmeasured confounders. This is impossible
to assert, but should be reasonable if we include any and all factors we believe to
be confounding. It can be checked through plots and tables that assess balance. To
check for balance, we can check how the KS statistic and standardized bias change
after weighting. Two plots are selected, as can be seen in figure 3.12. This plot shows
that after weighting, the standardized bias decreases for nearly every variable to an
acceptable level (below about .2 or .25 is considered balanced in the literature). As
well, it shows that the KS p-values are increasing, indicating that there is no difference
between the distributions of the pretreatment covariates after weighting.

Once propensity score validity is checked, the weights are put into the Cox model
for each MI dataset. We cannot be sure that our propensity scores are the truth (this
Figure 3.12: Selected propensity score balance checks

This figure shows how the balance is achieved for two different MI datasets. The left hand side denotes the maximum standardized bias for each of the two MI datasets for the pretreatment covariates in all groups. The right hand side shows the minimal p-value for the KS test among all groups in each of the two MI datasets.

is a known drawback of propensity score analysis), but we can be more confident that it is right by also including the pretreatment covariates as adjustments to the Cox model (along with weighting). This is known as being doubly robust estimator [12], or adjusting for the confounders.

The results for the unadjusted propensity score weighted and doubly robust adjusted methods can be seen in tables 3.9, 3.10, 3.11, and 3.12. As it can be seen,
when only accounting for the treatment effect alone, the estimate is quite unstable, but as we add in the other pretreatment covariates (many of which were actually in the original Cox model in the survival section), the results become more stable. The results are similar in trend to those obtained in the survival section. However, the interpretation is different. These results should be read as if the treatments were administered in a setting where the groups were similar at baseline (i.e. like an RCT). When removing all confounding factors, there seems to be a significant difference between Capecitabine and other chemotherapeutic drugs, but there seems to be no difference between Lapatinib and Trastuzumab in HER2+ patients. All drugs are, however, better than not taking any at all.

<table>
<thead>
<tr>
<th></th>
<th>AC Unweighted</th>
<th>AC IPTW</th>
<th>MI unweighted</th>
<th>MI IPTW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
</tr>
<tr>
<td>Cape. vs none</td>
<td>0.396 (0.325,0.482)</td>
<td>0.655 (0.481,0.894)</td>
<td>0.484 (0.400,0.585)</td>
<td>0.702 (0.543,0.906)</td>
</tr>
<tr>
<td>Other vs none</td>
<td>0.336 (0.287,0.394)</td>
<td>0.567 (0.46,0.754)</td>
<td>0.413 (0.354,0.481)</td>
<td>0.593 (0.470,0.748)</td>
</tr>
<tr>
<td>Cape. vs other</td>
<td>1.179 (0.983,1.416)</td>
<td>1.156 (0.966,1.383)</td>
<td>1.173 (0.981,1.402)</td>
<td>1.183 (0.998,1.404)</td>
</tr>
</tbody>
</table>

Table 3.9 : Unadjusted Chemotherapeutic ATE with IPTW, AC and MI

<table>
<thead>
<tr>
<th></th>
<th>AC Unweighted</th>
<th>AC IPTW</th>
<th>MI unweighted</th>
<th>MI IPTW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
<td>HR 95% CI</td>
</tr>
<tr>
<td>Cape. vs none</td>
<td>0.687 (0.530,0.891)</td>
<td>0.603 (0.443,0.820)</td>
<td>0.752 (0.595,0.952)</td>
<td>0.701 (0.536,0.917)</td>
</tr>
<tr>
<td>Other vs none</td>
<td>0.521 (0.416,0.653)</td>
<td>0.452 (0.340,0.602)</td>
<td>0.579 (0.474,0.707)</td>
<td>0.532 (0.416,0.681)</td>
</tr>
<tr>
<td>Cape. vs other</td>
<td>1.318 (1.078,1.612)</td>
<td>1.334 (1.109,1.604)</td>
<td>1.300 (1.076,1.570)</td>
<td>1.317 (1.100,1.579)</td>
</tr>
</tbody>
</table>

Table 3.10 : Chemotherapeutic ATE, doubly robust adjusted IPTW estimate, AC and MI
### Table 3.11: Unadjusted HER2-directed ATE with IPTW, AC and MI

<table>
<thead>
<tr>
<th></th>
<th>AC Unweighted</th>
<th>AC IPTW</th>
<th>MI Unweighted</th>
<th>MI IPTW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Lapat. vs none</td>
<td>0.467</td>
<td>(0.355,0.616)</td>
<td>0.571</td>
<td>(0.381,0.855)</td>
</tr>
<tr>
<td>Trastuz. vs none</td>
<td>0.488</td>
<td>(0.398,0.597)</td>
<td>0.566</td>
<td>(0.421,0.759)</td>
</tr>
<tr>
<td>Lapat. vs Trastuz.</td>
<td>0.958</td>
<td>(0.603,1.324)</td>
<td>1.009</td>
<td>(0.680,1.496)</td>
</tr>
</tbody>
</table>

### Table 3.12: HER2-directed ATE, doubly robust adjusted IPTW estimate, AC and MI

<table>
<thead>
<tr>
<th></th>
<th>AC Unweighted</th>
<th>AC IPTW</th>
<th>MI Unweighted</th>
<th>MI IPTW</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>HR</td>
<td>95% CI</td>
<td>HR</td>
<td>95% CI</td>
</tr>
<tr>
<td>Lapat. vs none</td>
<td>0.468</td>
<td>(0.316,0.692)</td>
<td>0.514</td>
<td>(0.331,0.798)</td>
</tr>
<tr>
<td>Trastuz. vs none</td>
<td>0.447</td>
<td>(0.328,0.6089)</td>
<td>0.456</td>
<td>(0.328,0.632)</td>
</tr>
<tr>
<td>Lapat. vs Trastuz.</td>
<td>1.048</td>
<td>(0.704,1.560)</td>
<td>1.128</td>
<td>(0.726,1.754)</td>
</tr>
</tbody>
</table>

Table 3.11: Unadjusted HER2-directed ATE with IPTW, AC and MI

Table 3.12: HER2-directed ATE, doubly robust adjusted IPTW estimate, AC and MI
Chapter 4

Discussion

Even though the analyses and interpretations in the survival and causal sections go about answering the question in different ways, the interpretations of them should be clear. For chemotherapeutic treatments, the analyses show that Capecitabine is not better than any other chemotherapeutic treatment, but any chemotherapeutic treatment is better than none. For HER2-directed therapies, it seems that there is no difference between Lapatinib and Trastuzumab, but that both are better than no HER2-directed therapy.

In the analysis, we often talk about “other” chemotherapeutic. However, this is not descriptive. In a future analysis, it would be wise to classify the other chemotherapeutic agents, so that analysis could be run to determine which drug is actually the best (in terms of hazard reduction or survival function change). Currently, all we know is that Capecitabine might not be the best chemotherapeutic drug, but we cannot say which is better.

We have discussed a number of tools and methods to analyze survival data with missingness and make causal inference. There are lots of decisions to be made along the way, and I am in no way advocating that my exact choices will be proper for all situations, I am only claiming that the decisions made were proper for the type of data and questions that we had. I hope that I have given the reader enough information to run their own analysis, even if they don’t choose the options that I did.

There will certainly be many disagreements about the multiple imputation por-
tion. And since the multiple imputation serves as the root of the analysis, the concerns should be addressed. The first concern comes from people who don’t understand or believe in imputation of missing values. Multiple imputation is a tool to help us find plausible values for missing data. We make no claim that each of the imputed values are correct, but when used properly, the results from subsequent analyses using the MI data will be unbiased. We aren’t using multiple imputation to create data where there is none, rather we are using it to “fill gaps” in places that we already do have data. We actually need to impute in certain cases if we want to get valid results, as analysis without imputation will lead to severely biased results [1].

The next and more substantial critique will come from statisticians who may not believe that the distribution that the imputations are being drawn from is valid. No matter what method we use to impute, we have to make a parametric assumption, be it the joint model for JM or the full conditionals for FCS. For our case, using the normal model is certainly wrong because we have so many categorical and strictly positive variables (which is proven to be suboptimal in [17]), so we are left only with using FCS. And FCS alone has weak theoretical justification. But as we have discussed before, many studies have shown that FCS is robust to non-compatibility. As well, there was no formal model validation (such as cross validation), only ad hoc checks. In the literature there is hardly any mention of validation, because if we were to cross validate, we would be drawing from different models, and comparison between the folds would be like comparing apples to oranges. As well, if we were to pick imputations based on a loss rule, we run the risk of picking imputations that minimize the loss, but are useless in practice [1].

To summarize about multiple imputation, I would say that it is a necessary evil. In the process of using multiple imputation, we lose predictive power, and are forced
to use a distribution that may not fit the data to a t. But we need to use imputation techniques if we wish to make any sense of our data with missingness. The advice I would give to those who are hesitant to use multiple imputation would be to not have missing data, but this is a task that is easier said than done. Multiple imputation is becoming the standard for missing data techniques, especially in the medical field. There are lots of pros to it, but there are certainly some cons. Much research has already gone in to MI, but much more needs to be done.

Next we can critique the survival section. We made a lot of assumptions about how our subjects were censored. We assumed that all of our subjects who were censored were right censored and non-informative. This seems to be a valid assumption, but there certainly exists left truncation. It may have been the case that there were some left truncated subjects, but once we landmarked, we certainly incurred some left truncation. When the log rank tests were performed, we needed to use many proxies to actually get the test result. Although it is theoretically justified, intuitively, it is not easy to follow. A topic for future research would be how to optimally combine MI test statistics, because currently the literature on it is slim and the methods are poor.

We decided to use Kaplan-Meier and Cox analyses because they are very standard in practice, and answer the questions well. However, some other methods could have been used. A popular theoretical model is called the accelerated failure time model (AFT), which describes how covariates affect the survival time, assuming that it acts in a multiplicative fashion. As well, we only focused on death data, and did not take into consideration competing risks. Had the dataset been more robust, perhaps we could have incorporated competing risks.

There are three concepts in survival analysis that I find interesting, but our data
did not allow for it. The first is variable selection. The clinicians knew what they
wanted to test, so this was not needed, but variable selection in the context of MI is
an interesting question, and van Buuren covers it in his book [1]. This would be very
useful if our dataset had covariates that we were unsure of their predictive power or
wanted to examine.

Another interesting addition would be using multistate data. In this setting,
subjects can transfer from one group to another, i.e. have cancer, metastasize to
the brain, go in to remission, and then relapse. We model the states as a stochastic
process. This would be really interesting, and I would have liked to implement it
because I think it would have been interesting from a multiple imputation perspective,
but unfortunately our data was not conducive to that.

Lastly, we move on to the causal analysis part. While propensity score analysis
is a popular tool to implement Rubin’s causal model, it is not the only one. Other
methods like instrumental variables also exist and are used in practice. There are
many critiques of the propensity score and the causal method in general. The as-
sumption of ignorability is central to the theory, but this assumption is theoretically
untestable. As well, the choice of pretreatment covariates entered into the propensity
score model, and the model itself were just chosen for convenience and balancing.
While they were both convenient and induced balance, there are certainly other pre-
dictors and models that could have achieved the same. This dilemma is a known
drawback of propensity score methods. This analysis chose to use propensity score
weighting, and while this is theoretically sound, many of the users of propensity scores
still prefer matching, because of its historical popularity. And lastly, we can never
draw causal inference from a statistical procedure, but we are able to emulate an
RCT, so that causal inferences are more justified than in traditional analyses.
An interesting topic for future research would be to use multiple imputation to impute the counterfactual with imputation. After all, the counterfactual framework is actually a missing data problem. It was decided to not use this method here, but using multiple imputation on an already imputed dataset seems like an interesting topic for further research.
Chapter 5

Conclusion

This paper details how to use multiply imputed data to answer survival and causal analysis questions. The motivation for the methods used is cancer data, although sufficient detail is given so that the methods can be applied towards other areas. The first section gives background information about multiple imputation, survival analysis, and causal analysis. In the second section, methods and theory are presented to prepare for a cancer data analysis. In the third section, we test the methods out on a large cancer dataset, trying to draw meaningful inference from a dataset with substantial missingness. It is determined in many different ways that for cancer patients, other chemotherapeutic drugs are better in terms of survival than Capecitabine, but that taking any chemotherapeutic drugs is better than not taking any at all. For HER2+ patients, it is shown that Lapatinib and Trastuzumab are about the same in terms of survival, but both are far superior than no HER2-directed treatment.
Appendix A

Appendix

A.1 Missing Data Mechanisms

There are three mechanisms of missing data. It is important to understand what type of missing data we have so that we can use methods that are suited for that type. Before we begin, we will need some notation. It is not constant throughout the literature, so I caution you to look at the author’s notation before reading any other literature. I will give the symbols I will be using along with words to describe them to make it easy to understand and explain.

- $Y$ is our whole dataset. It will have $n$ rows and $p$ columns (covariates). Some of the covariates in the dataset will be completely observed, and others will have missingness.

- $Y_j$ is a specific column of $Y$. $Y_j$ is composed as $Y_j = (Y_{j,obs}, Y_{j,mis})$, where
  - $Y_{j,obs}$ is the data we have observed for covariate $j$
  - $Y_{j,mis}$ is the missing data covariate $j$

- $Y_{obs}$ is all of the data that we have observed

- $Y_{mis}$ is all the data that we have not observed

- $R$ is a binary matrix the same size as $Y$ where a 1 indicates we observed the data, and 0 means it is missing
- $\psi$ is a vector of parameters for the missing data model.

- The missing data model is given as $p(R|Y_{obs}, Y_{mis}, \psi)$

- $\theta$ is a vector of the parameters for the full model of $Y$

As well, we have a concept called ignorability, which is defined as

$$p(Y_{mis}|Y_{obs}, R) = p(Y_{mis}|Y_{obs})$$

That is, we may “ignore” the $R$. The probability of the data being missing does not depend on how the data is missing. Equivalently, we may write this as

$$p(Y_{mis}|Y_{obs}, R = 1) = p(Y_{mis}|Y_{obs}, R = 0)$$

Being ignorable makes it justified to model our missing data from our observed data, without needing to worry about how it was missing. The opposite of ignorable data is called non-ignorable data, in this case,

$$p(Y_{mis}|Y_{obs}, R = 1) \neq p(Y_{mis}|Y_{obs}, R = 0)$$

So we must take into account the missing data structure for imputation. We often times see ignorable missing data in practice, although one should certainly check the sensibility of ignorability, as some instances will certainly be non-ignorable, for example censored data, or when we know that the missing data is systematically different than the observed. If we have strongly nonignorable data, we should either try one of two things. The first is to expand the data (collect something else similar to the covariate with missingness) so that it becomes ignorable and the second is to formulate two imputation models, one for the observed and one for the missing.

Now, we may discuss the three main types of missing data mechanisms. I will give the technical definition, a layman’s definition, and an example. For the example,
suppose there is a study that takes down subject information as well as records the level of a protein in the blood.

- **MCAR:** Missing completely at random: \( P(R = 0|Y_{obs}, Y_{mis}, \psi) = P(R = 0|\psi) \). The missingness in the data is not at all related to any of the data that we do or don’t have. For example, if a lab technician slips and drops 5 vials of blood, the missingness caused by this would be MCAR.

- **MAR:** Missing at random: \( p(R = 0|Y_{obs}, Y_{mis}, \psi) = p(R = 0|Y_{obs}, \psi) \). The missingness we have is related to something in the data. For example, if we collect the gender of the subject and we know that males tend to not give blood, we can attribute the missingness to the gender. In general, MAR models are ignorable [1].

- **MNAR:** Missing not at random: \( p(R = 0|Y_{obs}, Y_{mis}, \psi) \) does not simplify, and the missingness depends on data that we have as well as have not collected (i.e. the value of the missing data causes it to be missing). For example if the blood testing machine breaks and will not give the level when the protein level is either too high or too low.

A visualization of the missing data mechanisms may help in understanding the missing data mechanisms. In figure A.1, an example of each type of missing data mechanism is shown.
Figure A.1: Visualization of Missing Data Mechanisms

Red dots indicate missing values, and black dots denote observed values. In each plot, the X axis is a covariate with missingness, and the Y axis is a fully observed covariate.
A.2 Cancer and Treatment Overview

Cancer is a disease in mammals where cells in the body begin to grow in an uncontrolled manner [30]. There are many different types of cancers for the many different types of tissues we have in our bodies. This paper focuses on breast cancer.

Breast cancer is a common type of cancer with many different subclassifications, that affects both men and women, although women much more [30]. It can be inherited, but often can be detected early on with screening and self-examination. Most cases of breast cancer are sporadic, but studies have shown that a woman’s risk to get breast cancer is doubled if a first degree relative has breast cancer (i.e. it is genetic). When breast cancer is inherited, it often presents itself earlier in life [31]. One of the major risks of breast cancer is that it will metastasize, that is, the cancerous cells move from the breast to another area of the body. It should be noted that when a cancer metastasizes to another part of the body, the patient is said to have the original cancer metastasized to a new area, not a new cancer. For example, in this paper we study breast cancer patients who have metastases to the brain, not brain cancer patients. The reason for this is because the makeup of the cancer cell is the same type of tissue as the original location, not the new one.

Luckily, there are lots of different types of treatments for breast cancer and its metastases. I will list the major types here.

• Chemotherapy is a class of drugs given to cancer patients. These types of drugs target fast growing cells (like cancer) and kill them. Capecitabine is a common chemotherapeutic drug

• HER2-directed therapy: HER2 is a human protein that is associated with cell growth. If it is determined that the patient has the HER2 protein, then HER2-
directed therapies can be used. In HER2-directed therapies, a drug is given that targets the HER2 protein and tries to stop its effect. Common HER2 directed therapies include Lapatinib and Trastuzumab, which we discuss in this paper.

- Radiation therapy: When the cancer tumor is radiated by precisely located beams in hopes of killing or disturbing the cancer growth process by destroying the cancer DNA.

- Surgery/resection: A doctor goes in and physically removes the cancerous cells.

- Hormone therapy: Some cancers have hormone receptors in the tumor cells. The two main receptors are Estrogen Receptors (ER) and Progesterone Receptors (PR). These receptors pick up hormonal signals that tell the cancer cell to grow. If the patient is ER+ or PR+, then drugs that interfere with these receptors can be used.

Often times, a combination of these treatments are used. The exact course of treatment is very dependent on the type of cancer and the type of person. For example, chemotherapy is very difficult on the body, so it is not often used on the very elderly and frail. The course of treatment given should be determined by a subject matter expert (the oncologist), and is highly individual and cancer dependent. There have been many books and articles written about these, and for more information, you can check out [30] and [31].
Bibliography


